

ERIC QIONG WU, PH.D.
Managing Principal

Phone: 617 425 8254
Fax: 617 425 8001
eric.wu@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Dr. Wu is a health economist with expertise in health economics and outcomes research (HEOR), market access, and scientific evidence strategy. He has conducted research in more than 30 countries on behalf of pharmaceutical and medical device companies, payers, providers, and government agencies. Dr. Wu has contributed to over 200 publications across dozens of therapeutic areas, including regenerative therapies (gene and stem cell), rare and ultra-rare diseases, biologics, and immuno-oncology.

Dr. Wu spends a significant portion of his practice developing new scientific methods to address challenges in health care research. He has developed client-focused solutions based on the use of artificial intelligence (AI), medical big data, real-world evidence, and innovative comparative-effectiveness research methodologies.

EDUCATION

1998–2002	Ph.D. University of Southern California, Department of Pharmaceutical Economics and Policy School of Pharmacy
2001–2002	M.Sc. University of Southern California, Master’s Program in Regulatory Science (Regulation, Law, and Management in Health Care and Pharmaceutical Industry) School of Pharmacy
1998–2000	M.A. University of Southern California, Department of Economics, Successfully Completed the Ph.D. Core Theory Examinations for the Department of Economics
1993–1997	B.S. Peking University, Beijing, China, Biochemistry and Molecular Biology Department School of Life Sciences

PROFESSIONAL EXPERIENCE

2002–Present	Analysis Group, Inc.
2021–Present	Peking University Institute for Global Health and Development <i>Adjunct Faculty</i>

PUBLICATIONS

Articles in Peer-Reviewed Journals

1. “The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis,” Ryan C, Puig L, Zema C, Thompson EHZ, Yang

- M, Wu E, Bensimon A, Huang X, Joshi AD, Elewski B. *Journal of the American Academy of Dermatology*. 2023 01; 88(1):169-172. doi: 10.1016/j.jaad.2021.12.032.
2. “Health-care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis,” Chen YJ, Tang W, Ionescu-Ittu R, Ayyagari R, Wu E, Huh SY, Parkman HP. *Neurogastroenterology & Motility*. 2022 09; 34(9):e14366. doi: 10.1111/nmo.14366.
 3. “Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States,” Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. *Journal of Health Economics and Outcomes Research*. 2022 08; 9(2):19-29. doi: 10.36469/001c.36975.
 4. “The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States,” Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ. *Advances in Therapy*. 2022 08; 39(8):3547-3559. doi: 10.1007/s12325-022-02202-5.
 5. “Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018,” Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. *Advances in Therapy*. 2022 08; 39(8):3711-3734. doi: 10.1007/s12325-022-02173-7.
 6. “Advancing the development of real-world data for healthcare research in China: challenges and opportunities,” Zhong J, Zhang J, Fang H, Liu L, Xie J, Wu E. *BMJ Open*. 2022 07; 12(7):e063139. doi: 10.1136/bmjopen-2022-063139.
 7. “Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States,” Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD. *Journal of Managed Care & Specialty Pharmacy*. 2022 07; 28(7):740-752. doi: 10.18553/jmcp.2022.28.7.740.
 8. “Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018,” Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. *Advances in Therapy*. 2022. E-pub ahead of print 2022/06/24; doi: 10.1007/s12325-022-02173-7.
 9. Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United States. Lin F, Kwong WJ, Shi S, Pivneva I, Wu EQ, Abraham JA. *Journal of Health Economics and Outcomes Research*. 2022 Mar 4;9(1):68-74. Doi: 10.36469/jheor.2022.32485. eCollection 2022.
 10. Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis. Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ. *Advances in Therapy*. 2022 Feb;39(2):1033-1044. doi: 10.1007/s12325-021-02017-w. E-pub 2021 Dec 27.
 11. Real-World Data for Healthcare Research in China: Call for Actions. Xie J, Wu EQ, Wang S, Cheng T, Zhou Z, Zhong J, Liu L. *Value in Health Regional Issues*. 2022 Jan-Feb;27:72-81. doi: 10.1016/j.vhri.2021.05.002. E-pub 2021 Nov 26.

12. “Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations,” Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. *Value in Health*. 2021 11; 24(11):1628-1633. doi: 10.1016/j.jval.2021.05.008.
13. “Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia,” Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E. *Advances in Therapy*. 2021 11; 38(11):5596-5608. Doi: 10.1007/s12325-021-01925-1.
14. “Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia,” Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ. *Advances in Therapy*. 2021 10; 38(10):5238-5252. doi: 10.1007/s12325-021-01886-5.
15. “Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain,” Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferraris M. *Journal of Medical Economics*. 2021 08; 24(1):900-907. doi: 10.1080/13696998.2021.1953301.
16. “The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy,” Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S. *Advances in Therapy*. 2021 08; 38(8):4321-4332. doi: 10.1007/s12325-021-01843-2.
17. “Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan,” Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A. *Transplantation and Cellular Therapy*. 2021 06; 27(6):506.e1-506.e10. doi: 10.1016/j.jtct.2021.03.005.
18. “Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers,” Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D. *Neurology and Therapy*. 2021 06; 10(1):293-306. doi: 10.1007/s40120-021-00245-4.
19. “Health care resource utilization and cost burden of hemophilia B in the United States,” Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N. *Blood Advances*. 2021 04; 5(7):1954-1962. Doi: 10.1182/bloodadvances.2020003424.
20. “The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States,” Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu E, Kwong WJ, Abraham JA. *Journal of Occupational and Environmental Medicine*. 2021 04; 63(4):e197-e202. doi: 10.1097/JOM.0000000000002159.
21. Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers. Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D. *Neurology and Therapy*. 2021 Jun;10(1):293-306. Doi: 10.1007/s40120-021-00245-4. Epub 2021 Apr 15.

22. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X. *Leukemia & Lymphoma*. 2021 Jun;62(6):1411-1421. doi: 10.1080/10428194.2020.1869959. E-pub 2021 Jan 11.
23. “Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan,” Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A. *Transplantation and Cellular Therapy*. 2021 03; 27(3):241.e1-241.e11. doi: 10.1016/j.jtct.2020.12.023.
24. “Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis,” Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. *Journal of Medical Economics*. 2021 02; 24(1): 234-243. doi: 10.1080/13696998.2021.1876714.
25. “An overview of patients with hemophilia A in China: epidemiology, disease severity, and treatment strategies,” Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R. *Haemophilia*. 2021 01; 27(1): e51-e59. E-pub ahead of print: 2020/11/07; doi: 10.1111/hae.14217.
26. “Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials,” Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z Valdes JM, Joshi A, Gordon KB. *JAMA Dermatology*. 2020 Dec 1;156(12):1344-1353. doi: 10.1001/jamadermatol.2020.3617.
27. “The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China,” Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B. *Journal of Comparative Effectiveness Research*. 2020 11. E-pub ahead of print 2020/11/07; doi: 10.2217/cer-2020-0102.
28. “Healthcare Resource Use and Associated Costs in the Three Years Following the Initial Diagnosis of Diabetic or Idiopathic Gastroparesis: A Retrospective Claims Analysis,” Chen YJ, Tang W, Ionescu-Ittu R, Ayyagari R, Wu E, Huh SY, Parkman HP. *American Journal of Gastroenterology*. 2020 10; 115: S23-S24.
29. “Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China,” Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B. *Journal of Medical Economics* 2020 09; 23(12): 1630-1639. E-pub ahead of print 2020/09/30; doi: 10.1080/13696998.2020.1830410.
30. “Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era,” Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D. *Kidney Medicine* 2020 08; 2(5): 589-599.e1. doi: 10.1016/j.xkme.2020.06.008.
31. “Postdischarge Health Care Costs and Readmission in Patients with Hyperkalemia-Related Hospitalizations.” Betts KA, Woolley JM, Mu F, Wang Y, Wang Y, Dua A, Wu EQ. *Kidney International Reports*. 2020 07; 5(8): 1280-1290. E-pub ahead of print 2020/08/11; doi: 10.1016/j.ekir.2020.06.004.

32. “Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective.” Yang H, Hao Y, Qi CZ, Chai X, Wu EQ. *Journal of Managed Care & Specialty Pharmacy*. 2020 06; 0(0): 1-12. doi: 10.18553/jmcp.2020.20052.
33. “Prevalence and economic burden of hyperkalemia in the United States Medicare population.” Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ. *Current Medical Research and Opinion*. 2020 05: 1. E-pub ahead of print 2020/05/28; doi: 10.1080/03007995.2020.1775072.
34. “The estimated risk reduction of anaphylactic reactions associated with AR101 oral immunotherapy following accidental peanut exposure: an analysis based on clinical trial data.” Tilles S, Yu S, Smith A, Wu E, Zhou J, Chai X, Wei LJ, Robison DR, Hass SL, Donelson S, Vickery B. *Value in Health*. 2020 05; 23: S371. doi: 10.1016/j.jval.2020.04.1430.
35. “Oncology sequence models in health technology assessment-A literature review.” Xue W, Huang M, Ramsey SD, Gu C, Xie J, Wu E, Pellissier J, Briggs A. *Value in Health*, 2020 05; 23: S69-S70. doi: 10.1016/j.jval.2020.04.1732.
36. “Real-world analysis of haemophilia patients in China: A single centre’s experience.” Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, Xie J, Wu E, Zhang L, Shi J, Yang R. *Haemophilia*. 2020 05; n/a(n/a). doi: 10.1111/hae.14029.
37. “Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis,” Stein EM, Bonifacio G, Cao XY, Latremouille-Viau D, Guerin A, Shi S, Wu E. *Leukemia and Lymphoma*. 2020 05.
38. “A Review of Two Regulatory Approved Anti-CD19 CAR T-cell Therapies in Diffuse Large B-Cell Lymphoma: Why are Indirect Treatment Comparisons Not Feasible?” Zhang J, Li J, Ma Q, Yang H, Signorovitch j, Wu E. *Advances in Therapy*. 2020 05.
39. “Real-world analysis of hemophilia patients in China: A single center’s experience,” Song X, Liu W, Xue F, Zhong J, Yifan Y, Liu Y, Xie J, Wu E, Zhang L, Shi J, Yang R. *Haemophilia*. 2020 04.
40. “Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective.” Yang H, Hao Y, Chai X, Qi CZ, Wu EQ. *Journal of Medical Economics*. 2020 02: 1-1. doi: 10.1080/13696998.2020.1769109.
41. “Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system,” Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. *PloS One*. 2019 12; 14(12): e0225572. E-pub ahead of print 2019/12/05.
42. “Estimation of the healthcare resource utilization (HCRU) costs in patients with relapsed or refractory diffuse large b-cell lymphoma receiving tisagenlecleucel: a micro-costing study in the UK and France,” Yang H, Ma Q, Chai X, Zhang J, Wu EQ, Jousseau E, Kuzan D, Hao Y, Duteil E, Jewitt K. *Value in Health*. 2019 11; 22: S420.
43. “The Development of Health Technology Assessment in Asia: Current Status and Future Trends.” Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H. *Value in Health Regional Issues*. 2019 10; 21: 39-44. E-pub ahead of print 2019/10/22.

44. “Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer,” Fasching PA, Huang M, Cortes J, Zhao J, O’Shaughnessy J, Hu P, Haiderali A, Karantza V, Aktan G, Briggs A, Ramsey S, Qi CZ, Xie J, Gu C, Qian K, Yuan M, Wu EQ. *Annals of Oncology*. 2019 10; doi.org/10.1093/annonc/mdz240.067.
45. “Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.” Wu EQ, Zhou ZY, Xie J, Metallo C, Thokala P. *Pharmacoeconomics*. 2019 10. E-pub ahead of print 2019/10/09.
46. “Letter to the Editor, Response to Alfred Sandrock and Wildon Farwell’s ‘Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, et al.’” *Advances in Therapy*. 2019. 36(5):1164-76. doi:10.1007/s12325-019-00923-8.” Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. *Advances in Therapy*. 2019 09. E-pub ahead of print 2019/09/13; doi: 10.1007/s12325-019-01088-0.
47. “Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections,” Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. *Advances in Therapy*. 2019 06. E-pub ahead of print 2019/06/27; doi: 10.1007/s12325-019-01012-6.
48. “Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review,” Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. *Advances in Therapy*. 2019 06. E-pub ahead of print 2019/06/07; doi: 10.1007/s12325-019-00998-3.
49. “Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1,” Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. *Advances in Therapy*. 2019 03; doi: 10.1007/s12325-019-00923-8.
50. “Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy.” Qi CZ, Huang M, Haiderali A, Xie J, Zhou Z-Y, Wu EQ, Fasching P. *JNCCN – Journal of the National Comprehensive Cancer Network*. 2019 03; 17(3.5). E-pub ahead of print 2019/03/08.
51. “Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration,” Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thastrom A, Liu S, Shi L, Leppert JT. *European Urology Oncology* 2019 02; 2(1): 12-20. E-pub ahead of print 2019/04/02; doi: 10.1016/j.euo.2018.07.003.
52. “Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data,” Fu Y, Han S, Wang L, Gao W, Wu E, Cao X, Wang J. *Advances in Therapy*. 2018 08; 35(8): 1191-1198. doi: 10.1007/s12325-018-0748-3.

53. “Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer,” Guerin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA. *Advances in Therapy*. 2018 08; 35(8): 1251-1264. E-pub ahead of print 2018/06/28; doi: 10.1007/s12325-018-0740-y.
54. “Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis,” Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ. *Current Medical Research and Opinion*. 2018 07; 34(7): 1325-1333. E-pub ahead of print 2018/04/06; doi: 10.1080/03007995.2018.1457516.
55. “Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis,” Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R. *Diabetes Therapy*. 2018 06; 9(3): 1021-1036. E-pub ahead of print 2018/03/31; doi: 10.1007/s13300-018-0410-8.
56. “The prevalence of hyperkalemia in the United States,” Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. *Current Medical Research and Opinion*. 2018 06; 34(6): 971-978. E-pub ahead of print 2018/01/26; doi: 10.1080/03007995.2018.1433141.
57. “A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment,” Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S. *Journal of Clinical Hypertension*. 2018 06; 20(6): 1058-1066. E-pub ahead of print 2018/06/15; doi: 10.1111/jch.13312.
58. “Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study,” Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T. *Advances in Therapy*. 2018 04; 35(4): 482-493. E-pub ahead of print 2018/03/28; doi: 10.1007/s12325-018-0676-2.
59. “The Cost of Hyperkalemia in the United States,” Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. *Kidney International Reports*. 2018 03; 3(2): 385-393. E-pub ahead of print 2018/05/05; doi: 10.1016/j.ekir.2017.11.003.
60. “The economic burden of bipolar I disorder in the United States in 2015,” Cloutier M, Greene M, Guerin A, Touya M, Wu E. *Journal of Affective Disorders*. 2018 01; 226: 45-51. E-pub ahead of print 2017/09/30; doi: 10.1016/j.jad.2017.09.011.
61. “Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials,” Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM. *Journal of the American Academy of Dermatology*. 2017 12; 77(6): 1030-1037. E-pub ahead of print 2017/10/11; doi: 10.1016/j.jaad.2017.08.017.
62. “Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer,” Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA. *Advances in Therapy*. 2017 12; 34(12): 2566-2584. E-pub ahead of print 2017/11/17; doi: 10.1007/s12325-017-0644-2.

63. “Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders,” Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP. *Journal of Managed Care & Specialty Pharmacy*. 2017 10; 23(10): 1018-1026. E-pub ahead of print 2017/09/26; doi: 10.18553/jmcp.2017.23.10.1018.
64. “Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator,” Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ. *Journal of Stroke and Cerebrovascular Diseases*. 2017 09; 26(9): 1996-2003. E-pub ahead of print 2017/07/12; doi: 10.1016/j.jstrokecerebrovasdis.2017.06.010.
65. “Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests,” Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ. *Journal of Medical Economics*. 2017 08; 20(8): 777-785. E-pub ahead of print 2017/04/14; doi: 10.1080/13696998.2017.1314969.
66. “Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis,” Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. *Journal of Managed Care & Specialty Pharmacy*. 2017 07; 23(7): 771-780. E-pub ahead of print 2017/06/27; doi: 10.18553/jmcp.2017.23.7.771.
67. “Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study,” Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R. *Diabetes Therapy*. 2017 06; 8(3): 555-571. E-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.
68. “Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy,” Soliman AM, Du EX, Yang H, Wu EQ, Haley JC. *Journal of Womens Health*. 2017 06; 26(6): 644-654. doi: 10.1089/jwh.2016.6043.
69. “Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy,” Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. *Hepatology Communications*. 2017 05; 1(5): 439-452. doi: <http://dx.doi.org/10.1002/hep4.1049>.
70. “A Risk Score for Fluconazole Failure among Patients with Candidemia,” Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ. *Antimicrobial Agents and Chemotherapy*. 2017 05; 61(5). E-pub ahead of print 2017/03/08; doi: 10.1128/AAC.02091-16.
71. “Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease,” Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. *Journal of Clinical Movement Disorders*. 2017 03; 4: 3. E-pub ahead of print 2017/03/08; doi: 10.1186/s40734-017-0051-5.
72. “Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists,” Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ. *Drugs Real World Outcomes*. 2017 03; 4(1): 33-41. E-pub ahead of print 2016/11/20; doi: 10.1007/s40801-016-0097-y.

73. “Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer,” Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. *Journal of Medical Economics*. 2017 02; 20(2): 121-128. doi: 10.1080/13696998.2016.1229670.
74. “Real-world costs of ischemic stroke by discharge status,” Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ. *Current Medical Research and Opinion*. 2017 02; 33(2): 371-378. E-pub ahead of print 2016/11/09; doi: 10.1080/03007995.2016.1257979.
75. “Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis,” Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. *Advances in Therapy*. 2017 01; 34(1): 207-220. E-pub ahead of print 2016/12/04; doi: 10.1007/s12325-016-0443-1.
76. “Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant,” Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanova M, Wu EQ, Thomas SK, Chen L. *International Journal of Hematologic Oncology*. 2016 09; 5(2): 63-75. doi: <http://dx.doi.org/10.2217/ijh-2016-0001>.
77. “Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A,” Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J. *Journal of Blood Medicine*. 2016 07; 7: 129-137. E-pub ahead of print 2016/07/23; doi: 10.2147/JBM.S104074.
78. “Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis,” Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A. *Rheumatology Therapeutics*. 2016 07; 1-14. doi: 10.1007/s40744-016-0038-y.
79. “Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients,” Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. *Antimicrobial Agents and Chemotherapy*. 2016 06; 60(6): 3398-3406. E-pub ahead of print 2016/03/24; doi: 10.1128/AAC.00054-16.
80. “The Economic Burden of Schizophrenia in the United States in 2013,” Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C, Wu E. *Journal of Clinical Psychiatry*. 2016 06; 77(6): 764-771. E-pub ahead of print 2016/05/03; doi: 10.4088/JCP.15m10278.
81. “Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy,” Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A. *Advances in Therapy*. 2016 06; 33(6): 983-997. doi: 10.1007/s12325-016-0328-3.
82. “Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study,” Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. *Expert Opinion on Pharmacotherapy*. 2016 06; 17(9): 1189-1196. E-pub ahead of print 2016/04/08; doi: 10.1080/14656566.2016.1176148.

83. “Cost impact of switching from metoprolol to nebivolol for hypertension,” Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E. *American Journal of Pharmacy Benefits*. 2016 05; 8(3): e48-e54, 15-16.
84. “Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer,” Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B. *Breast Cancer Research and Treatment*. 2016 05; 157(1): 145-156. E-pub ahead of print 2016/04/25; doi: 10.1007/s10549-016-3790-3.
85. “Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis,” Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. *Clinical Therapeutics*. 2016 05; 38(5): 1205-1216. E-pub ahead of print 2016/04/06; doi: 10.1016/j.clinthera.2016.03.013.
86. “The economic burden of brain metastasis among lung cancer patients in the United States,” Guerin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR. *Journal of Medical Economics*. 2016 05; 19(5): 526-536. doi: 10.3111/13696998.2016.1138962.
87. “Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis,” Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A. *Journal of Medical Economics*. 2016 04; 19(4): 414-423. doi: 10.3111/13696998.2015.1131704.
88. “Effectiveness of Everolimus versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients with Multiple Metastatic Sites,” Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. *Clinical Therapeutics*. 2016 04; 38(4): 905-917. E-pub ahead of print 2016/03/08; doi: 10.1016/j.clinthera.2016.02.009.
89. “Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis,” Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A. *Neurology*. 2016 04; 86(16 SUPPL. 1). E-pub ahead of print April 8, 2016.
90. “Variation in Care for Patients with Irritable Bowel Syndrome in the United States,” Lacy BE, Patel H, Guerin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R. *PLoS One*. 2016 04; 11(4): e0154258. E-pub ahead of print 2016/04/27; doi: 10.1371/journal.pone.0154258.
91. “Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective,” Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R. *Current Medical Research and Opinion*. 2016 03; 32(3): 405-416. E-pub ahead of print 2015/11/14; doi: 10.1185/03007995.2015.1119678.
92. “Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice,” Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B. *SpringerPlus*. 2016 03; 5: 395. E-pub ahead of print 2016/04/06; doi: 10.1186/s40064-016-2008-9.
93. “Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey,” Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. *Cancer Medicine*. 2016 02; 5(2): 209-220. doi: 10.1002/cam4.580.

94. “Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis,” Freemantle N, Chou E, Frois C, Zhuo D, Lehmacher W, Vlajnic A, Wang H, Chung HW, Zhang Q, Wu E, Gerrits C. *BMJ Open*. 2016 02; 6(2): e009421. E-pub ahead of print 2016/02/18; doi: 10.1136/bmjopen-2015-009421.
95. “Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US,” Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A. *Current Medical Research and Opinion*. 2016 02; 32(2): 385-394.
96. “Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication,” Guerin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E. *PloS One*. 2016 01; 11(1): e0145504. doi: 10.1371/journal.pone.0145504.
97. “Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization,” Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. *Respiratory Medicine*. 2015 12; 109(12): 1582-1588. doi: 10.1016/j.rmed.2015.11.001.
98. “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. *BMC Pulmonary Medicine*. 2015 12; 15(167): 167. doi: 10.1186/s12890-015-0161-5.
99. “Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US,” Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ. *Experimental Hematology & Oncology*. 2015 12; 4(31): 31. doi: 10.1186/s40164-015-0023-0.
100. “Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment,” Chen L, Wu EQ. *Journal of Managed Care & Specialty Pharmacy*. 2015 11; 21(11): 1088. doi: 10.18553/jmcp.2015.21.11.1088.
101. “Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA,” Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. *Expert Opinion on Pharmacotherapy*. 2015 10; 16(14): 2101-2111. doi: 10.1517/14656566.2015.1074182.
102. “Characteristics of non-small cell lung cancer (NSCLC) patients who underwent curative-intent surgical resections in China,” Zhou J, Han S, Yang F, Wu E.Q, Xie J, Wang X, Li H, Wang J. *Journal of Thoracic Oncology*. 2015 09; 10(9 SUPPL. 2): S380.
103. “Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer,” Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ. *Breast Cancer*. 2015 09; 9: 67-72. doi: 10.4137/BCBCR.S30771.
104. “Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study,” Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA. *Diabetes Therapy*. 2015 09; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2.
105. “Patient outcomes following curative-intent lung resection among non-small cell lung cancer (NSCLC) patients in China,” Zhou J, Wu E.Q, Yang F, Xie J, Han S, Wang X, Song H, Wang J. *Journal of Thoracic Oncology*. 2015 09; 10(9 SUPPL. 2): S677.

106. “Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection,” Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP. *JAMA Oncology*. 2015 09; 1(6): 797-805. doi: 10.1001/jamaoncol.2015.2407.
107. “Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer,” Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. *Current Medical Research and Opinion*. 2015 08; 31(8): 1573-1582. E-pub ahead of print 2015/06/16; doi: 10.1185/03007995.2015.1062358.
108. “Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer,” Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. *Journal of Comparative Effectiveness Research*. 2015 08; 4(4): 315-326. E-pub ahead of print 2015/08/15; doi: 10.2217/ce.15.25.
109. “Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study,” Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R. *Current Medical Research and Opinion*. 2015 08; 31(8): 1611-1620. doi: 10.1185/03007995.2015.1062750.
110. “Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting,” Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM. *Cancer Medicine*. 2015 08; 4(8): 1205-1213. doi: 10.1002/cam4.475.
111. “ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer,” Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. *Cancer Epidemiology*. 2015 06; 39(3): 307-312. doi: 10.1016/j.canep.2015.04.005.
112. “Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US,” Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. *Current Medical Research and Opinion*. 2015 06; 31(6): 1095-1103. E-pub ahead of print 2015/05/15; doi: 10.1185/03007995.2015.1021906.
113. “Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States,” Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. *Clinical Therapeutics*. 2015 06. doi: 10.1016/j.clinthera.2015.05.503.
114. “Psoriasis and risk of diabetes-associated microvascular and macrovascular complications,” Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P. *Journal of the American Academy of Dermatology*. 2015 06; 72(6): 968-977 e962. doi: 10.1016/j.jaad.2015.02.1095.
115. “Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis,” Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D. *Current Medical Research and Opinion*. 2015 05; 31(7): 1377-1389. doi: 10.1185/03007995.2015.1048208.

116. “Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data,” Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D. *Current Medical Research and Opinion*. 2015 05; 31(5): 993-1001. doi: 10.1185/03007995.2015.1030378.
117. “Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study,” Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. *International Journal of Breast Cancer*. 2015 05; 2015: 240750. doi: 10.1155/2015/240750.
118. “Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden,” Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. *Journal of Medical Economics*. 2015 04; 18(4): 312-322. doi: 10.3111/13696998.2014.1003644.
119. “Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir,” Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ. *Journal of Managed Care & Specialty Pharmacy*. 2015 04; 21(4): 308-318.
120. “Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment,” Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. *Value in Health*. 2015 03; 18(2): 198-205. doi: 10.1016/j.jval.2014.12.016.
121. “The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas,” Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. *Current Medical Research and Opinion*. 2015 03; 31(3): 537-545. doi: 10.1185/03007995.2015.1008131.
122. “Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names,” Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P. *Advances in Therapy*. 2015 03; 32(3): 270–283. doi: 10.1007/s12325-015-0193-5.
123. “Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response,” Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P. *British Journal of Dermatology*. 2015 02; 172(2): 504-512. doi: 10.1111/bjd.13437.
124. “Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis,” Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E. *Current Medical Research and Opinion*. 2015 02: 1-30. doi: 10.1185/03007995.2015.1013624.
125. “Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010),” Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C. *Current Medical Research and Opinion*. 2015 02; 31(02): 263-273. doi: 10.1185/03007995.2014.980885.

126. “Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases,” Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. *Fertility and Sterility*. 2015 01; 103(1): 163-171. doi: 10.1016/j.fertnstert.2014.10.011.
127. “Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study,” Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. *Lung Cancer*. 2014 12; 86(3): 350-357. doi: 10.1016/j.lungcan.2014.09.017.
128. “The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy,” Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ. *Journal of Medical Economics*. 2014 12: 1-8. doi: 10.3111/13696998.2014.991787.
129. “Prevalence and risk of developing comorbid conditions in patients with chronic constipation,” Mody R, Guerin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. *Current Medical Research and Opinion*. 2014 12; 30(12): 2505-2513. doi: 10.1185/03007995.2014.964854.
130. “Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients—a chart extract-based approach,” Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. *Journal of Gastrointestinal Cancer*. 2014 12; 45(4): 431-440. doi: 10.1007/s12029-014-9600-4.
131. “Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase,” Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ. *Current Medical Research and Opinion*. 2014 11; 30(11): 2317-2328. doi: 10.1185/03007995.2014.944973.
132. “One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison,” Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ. *Current Medical Research and Opinion*. 2014 11: 1–8. doi: 10.1185/03007995.2014.977992.
133. “The impact of moderate-to-severe Crohn’s Disease on employees’ salary growth,” Loftus EV, Jr., Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P. *Inflammatory Bowel Diseases*. 2014 10; 20(10): 1734–1738. doi: 10.1097/MIB.000000000000133.
134. “Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis,” Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ. *Journal of Medical Economics*. 2014 09; 17(9): 646–657. doi: 10.3111/13696998.2014.925905.
135. “Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder,” Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ. *American Journal of Managed Care*. 2014 09; 20(9): 711–721.
136. “Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting,” Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D. *Oncologist*. 2014 09; 19(9): 901-908. doi: 10.1634/theoncologist.2014-0059.

137. “The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population,” Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. *Journal of Medical Economics*. 2014 08; 17(8): 577-586. doi: 10.3111/13696998.2014.919926.
138. “Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase,” Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL. *Current Medical Research and Opinion*. 2014 07; 30(7): 1345-1352. doi: 10.1185/03007995.2014.904281.
139. “Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation,” Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. *Alimentary Pharmacology and Therapeutics*. 2014 07; 40(1): 83-92. doi: 10.1111/apt.12789.
140. “Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis,” DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ. *Clinical Lymphoma, Myeloma & Leukemia*. 2014 06; 14(3): 245-251. doi: 10.1016/j.clml.2013.12.002.
141. “Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009,” Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ. *Journal of Child and Adolescent Psychopharmacology*. 2014 06; 24(5): 260-268. doi: 10.1089/cap.2013.0107.
142. “Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis,” Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG. *SpringerPlus*. 2014 05; 3: 236. doi: 10.1186/2193-1801-3-236.
143. “Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy,” Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E. *Postgraduate Medicine*. 2014 05; 126(3): 47-55. doi: 10.3810/pgm.2014.05.2755.
144. “Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension,” Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ. *Current Medical Research and Opinion*. 2014 04; 30(4): 637-643. doi: 10.1185/03007995.2013.864267.
145. “Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis,” Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. *Cancer Treatment Reviews*. 2014 03; 40(2): 285-292. doi: 10.1016/j.ctrv.2013.09.004.
146. “The role of health economics and outcomes research in health care reform in China,” Liang W, Xie J, Fu H, Wu EQ. *Pharmacoeconomics*. 2014 03; 32(3): 231-234. doi: 10.1007/s40273-014-0141-2.
147. “Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China,” Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. *Pharmacoeconomics*. 2014 03; 32(3): 305-313. doi: 10.1007/s40273-014-0131-4.

148. “Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States,” Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. *Applied Health Economics and Health Policy*. 2014 02; 12(1): 85-93. doi: 10.1007/s40258-013-0072-7.
149. “Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia,” Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL. *Journal of Medical Economics*. 2014 02; 17(2): 89-98. doi: 10.3111/13696998.2013.862251.
150. “Cost utility of hub-and-spoke telestroke networks from societal perspective,” Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ. *American Journal of Managed Care*. 2013 12; 19(12): 976-985.
151. “Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States (Re.),” Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. *Journal of Medical Economics*. 2013 12; 16(2): 260-262. doi: 10.3111/13696998.2012.752738.
152. “Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States,” Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. *Journal of Medical Economics*. 2013 11; 16(2): 278-288. doi: 10.3111/13696998.2012.749788.
153. “Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology,” Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ. *CNS Drugs*. 2013 11; 27(11): 943-953. doi: 10.1007/s40263-013-0102-x.
154. “Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors,” Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A. *Journal of Medical Economics*. 2013 11; 16(2): 221-230. doi: 10.3111/13696998.2012.749789.
155. “Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications,” Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH. *Journal of Medical Economics*. 2013 11; 16(11): 1275-1289. doi: 10.3111/13696998.2013.839947.
156. “Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes,” Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA. *Diabetes Care*. 2013 10; 36(10): 3297-3304. doi: 10.2337/dc13-0149.
157. “Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults,” Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH. *Journal of Medical Economics*. 2013 10; 16(10): 1203-1215. doi: 10.3111/13696998.2013.832258.
158. “Development and validation of a claims-based prediction model for COPD severity,” Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF. *Respiratory Medicine*. 2013 10; 107(10): 1568-1577. doi: 10.1016/j.rmed.2013.05.012.

159. “A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care,” Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L. *Pediatric Pulmonology*. 2013 10; 48(10): 954-961. doi: 10.1002/ppul.22741.
160. “Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib,” Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ. *Current Medical Research and Opinion*. 2013 09; 29(9): 1075-1082. doi: 10.1185/03007995.2013.812034.
161. ”Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia,” Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L. *Journal of Oncology Practice*. 2013 09; 9(5): e212-219. doi: 10.1200/JOP.2012.000822.
162. “Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout,” Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L. *QJM*. 2013 08; 106(8): 721-729. doi: 10.1093/qjmed/hct093.
163. “Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis,” Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH. *Journal of Medical Economics*. 2013 07; 16(7): 962-975. doi: 10.3111/13696998.2013.800524.
164. “Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy,” Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS. *International Journal of Cardiology*. 2013 07; 167(2): 564-569. doi: 10.1016/j.ijcard.2012.01.047.
165. “Serum urate and incidence of kidney disease among veterans with gout,” Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L. *Journal of Rheumatology*. 2013 07; 40(7): 1166-1172. doi: 10.3899/jrheum.121061.
166. “Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis,” Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ. *Current Medical Research and Opinion*. 2013 06; 29(6): 623-631. doi: 10.1185/03007995.2013.789012.
167. “Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy – a retrospective chart extract-based approach,” Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. *Journal of Gastrointestinal Cancer*. 2013 06; 44(2): 190-198. doi: 10.1007/s12029-012-9467-1.
168. “The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors,” Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. *Journal of Medical Economics*. 2013 06; 16(1): 125-133. doi: 10.3111/13696998.2012.693896.
169. “A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus,” Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C. *Journal of Medical Economics*. 2013 05; 16(6): 793-800. doi: 10.3111/13696998.2013.802241.

170. “Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs,” Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM. *Diabetes, Obesity and Metabolism*. 2013 04; 15(4): 335-341. doi: 10.1111/dom.12031.
171. “Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals’ perspectives,” Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ. *Circulation: Cardiovascular Quality and Outcomes*. 2013 01; 6(1): 18-26. doi: 10.1161/CIRCOUTCOMES.112.967125.
172. “Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy,” Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M. *American Journal of Therapeutics*. 2012 11; 19(6): e157-166. doi: 10.1097/MJT.0b013e31820543c5.
173. “Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics,” Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ. *Journal of Managed Care Pharmacy*. 2012 11; 18(9): 676-689.
174. “Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison,” Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V. *Applied Health Economics and Health Policy*. 2012 11; 10(6): 381-395. doi: 10.2165/11641870-000000000-00000.
175. “Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis,” Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. *Current Medical Research and Opinion*. 2012 11; 28(11): 1831-1839. doi: 10.1185/03007995.2012.741577.
176. “Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research,” Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ. *Value in Health*. 2012 10; 15(6): 940-947. doi: 10.1016/j.jval.2012.05.004.
177. “Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital,” Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. *Hospital Practice*. 2012 10; 40(4): 40-48. doi: 10.3810/hp.2012.10.1002.
178. “Risks of developing psychiatric disorders in pediatric patients with psoriasis,” Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM. *Journal of the American Academy of Dermatology*. 2012 10; 67(4): 651-657 e651-652. doi: 10.1016/j.jaad.2011.11.948.
179. “Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization,” Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. *Endocrine Practice*. 2012 09; 18(5): 651-659. doi: 10.4158/EP11314.OR.

180. “Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents,” Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ. *Pharmacoeconomics*. 2012 08; 30(8): e1-15. doi: 10.2165/11632920-000000000-00000.
181. “Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases,” Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. *Clinical Breast Cancer*. 2012 08; 12(4): 247-258. doi: 10.1016/j.clbc.2012.04.001.
182. “Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review,” Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH. *CNS Drugs*. 2012 07; 26(7): 581-600. doi: 10.2165/11633900-000000000-00000.
183. “Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis,” Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. *Advances in Therapy*. 2012 07; 29(7): 620-634. doi: 10.1007/s12325-012-0035-7.
184. “A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting,” Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD. *Current Medical Research and Opinion*. 2012 07; 28(7): 1155-1162. doi: 10.1185/03007995.2012.705264.
185. “Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity,” Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. *Journal of Medical Economics*. 2012 06; 15(6): 1078-1087. doi: 10.3111/13696998.2012.689270.
186. “Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder,” Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ. *Pharmacoepidemiology and Drug Safety*. 2012 05; 21 Suppl 2: 130-137. doi: 10.1002/pds.3246.
187. “Economic burden and quality of life of vulvodinia in the United States,” Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C. *Current Medical Research and Opinion*. 2012 04; 28(4): 601-608. doi: 10.1185/03007995.2012.666963.
188. “Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis,” Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S. *Current Medical Research and Opinion*. 2012 04; 28(4): 591-599. doi: 10.1185/03007995.2012.668495.
189. “Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients,” Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. *Journal of Medical Economics*. 2012 04; 15(4): 786-795. doi: 10.3111/13696998.2012.682632.

190. "Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs," Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. *Postgraduate Medicine*. 2012 01; 124(1): 124-132. doi: 10.3810/pgm.2012.01.2525.
191. "Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution," Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. *Pediatric Pulmonology*. 2012 01; 47(1): 44-52. doi: 10.1002/ppul.21521.
192. "Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population," Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH. *Managed Care*. 2012 01; 21(1): 49-58.
193. "Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD," Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. *Respiratory Medicine*. 2011 12; 105(12): 1861-1871. doi: 10.1016/j.rmed.2011.07.001.
194. "Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients," Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A. *American Journal of Pharmacy Benefits*. 2011 12; 3(6): e111-e120. E-pub ahead of print Dec 6, 2011.
195. "Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD," Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ. *Journal of Medical Economics*. 2011 10; 14(6): 805-815. doi: 10.3111/13696998.2011.623204.
196. "Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases," Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW. *Journal of Managed Care Pharmacy*. 2011 10; 17(8): 621-643.
197. "5002 ORAL Complications Associated with Chemotherapy in Patients with Metastatic Breast Cancer," Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu A, Wu E, Hurvitz S. *European Journal of Cancer*. 2011 09; 47: S330.
198. "Increased risks of developing anxiety and depression in young patients with Crohn's disease," Loftus EV, Jr., Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM. *American Journal of Gastroenterology*. 2011 09; 106(9): 1670-1677. doi: 10.1038/ajg.2011.142.
199. "Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials," Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. *Clinical Drug Investigation*. 2011 08; 31(9): 665-674. doi: 10.2165/11592490-000000000-00000.
200. "Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma," Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. *Clinical Lymphoma, Myeloma & Leukemia*. 2011 08; 11(4): 326-335. doi: 10.1016/j.clml.2011.04.004.
201. "Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer," Yang H, Yu AP, Wu EQ, Yim YM, Yu E. *Journal of Medical Economics*. 2011 07; 14(5): 542-552. doi: 10.3111/13696998.2011.596600.

202. “Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials,” Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. *Current Medical Research and Opinion*. 2011 06; 27(6): 1263-1271. doi: 10.1185/03007995.2011.576238.
203. “Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs,” Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH. *Journal of Medical Economics*. 2011 06; 14(4): 508-515. doi: 10.3111/13696998.2011.593602.
204. “Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors,” Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH. *Current Medical Research and Opinion*. 2011 06; 27(6): 1089-1096. doi: 10.1185/03007995.2011.567255.
205. “Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers,” Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. *Journal of Medical Economics*. 2011 06; 14(4): 486-496. doi: 10.3111/13696998.2011.594123.
206. “Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder,” Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. *Annals of Pharmacotherapy*. 2011 04; 45(4): 441-451. doi: 10.1345/aph.1P482.
207. “Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis,” Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. *Journal of Medical Economics*. 2011 04; 14(3): 315-323. doi: 10.3111/13696998.2011.576295.
208. “Switch to generic SSRIs may boost costs in MDD,” Wu E. *PharmacoEconomics & Outcomes News*. 2011 04; 625: 2.
209. “The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population,” Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L. *Prostate Cancer and Prostatic Diseases*. 2011 03; 14(1): 79-84. doi: 10.1038/pcan.2010.49.
210. “Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram,” Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH. *American Health & Drug Benefits*. 2011 03; 4(2): 78-87.
211. “Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy,” Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP. *Journal of Medical Economics*. 2011 03; 14(3): 267-278. doi: 10.3111/13696998.2011.570401.
212. “Refractory gout brings economic pain,” Wu E. *PharmacoEconomics & Outcomes News*. 2011 03; 623: 5.

213. “Economic burden of comorbidities in patients with psoriasis is substantial,” Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Journal of the European Academy of Dermatology and Venereology*. 2011 02; 25(2): 157-163. doi: 10.1111/j.1468-3083.2010.03730.x.
214. “Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with comorbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial,” Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. *American Journal of Clinical Dermatology*. 2011 02; 12(1): 51-62. doi: 10.2165/11530640-000000000-00000.
215. “Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus,” Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ. *Current Medical Research and Opinion*. 2011 01; 27(1): 189-195. doi: 10.1185/03007995.2010.536755.
216. “Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension,” Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ. *American Journal of Cardiovascular Drugs*. 2011 01; 11(1): 21-32. doi: 10.2165/11586570-000000000-00000.
217. “Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn’s disease,” Loftus EV, Jr., Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J. *Inflammatory Bowel Diseases*. 2011 01; 17(1): 127-140. doi: 10.1002/ibd.21341.
218. “Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy,” Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder MH, Bose A. *American Journal of Pharmacy Benefits*. 2011.
219. “Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial,” Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Journal of the American Academy of Dermatology*. 2010 12; 63(6): 1011-1018. doi: 10.1016/j.jaad.2009.12.029.
220. “Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia,” Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. *Current Medical Research and Opinion*. 2010 12; 26(12): 2861-2869. doi: 10.1185/03007995.2010.533648.
221. “The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy,” Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. *Alimentary Pharmacology and Therapeutics*. 2010 11; 32(10): 1228-1239. doi: 10.1111/j.1365-2036.2010.04466.x.
222. “Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials,” Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Dermatology*. 2010 11; 220(1): 1-7. doi: 10.1159/000260371.

223. “Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study,” Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M. *Journal of Medical Economics*. 2010 10; 13(4): 599-609. doi: 10.3111/13696998.2010.521736.
224. “Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement,” Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ. *Current Medical Research and Opinion*. 2010 09; 26(9): 2203-2212. doi: 10.1185/03007995.2010.500883.
225. “Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept,” Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. *Pharmacoeconomics*. 2010 09; 28(10): 935-945. doi: 10.2165/11538370-000000000-00000.
226. “Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives,” Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. *Current Medical Research and Opinion*. 2010 09; 26(9): 2065-2076. doi: 10.1185/03007995.2010.494462.
227. “The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial,” Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. *Journal of the American Academy of Dermatology*. 2010 05; 62(5): 812-818. doi: 10.1016/j.jaad.2009.07.022.
228. “Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons,” Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A. *Journal of Medical Economics*. 2010 05; 13(2): 314-323. doi: 10.3111/13696998.2010.488985.
229. “Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension,” Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. *Current Medical Research and Opinion*. 2010 04; 26(4): 849-860. doi: 10.1185/03007991003613910.
230. “Systematic review: the costs of ulcerative colitis in Western countries,” Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. *Alimentary Pharmacology and Therapeutics*. 2010 04; 31(7): 693-707. doi: 10.1111/j.1365-2036.2010.04234.x.
231. “High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice,” Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Dermatology*. 2010 02; 220(2): 128-137. doi: 10.1159/000275198.
232. “Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients,” Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. *Current Medical Research and Opinion*. 2010 01; 26(1): 61-69. doi: 10.1185/03007990903396469.

233. “Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs Single Long-Acting Inhalers,” Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI. *CHEST Journal*. 2010 138(4_MeetingAbstracts): 482A-482A.
234. “Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol,” Frois C, Wu EQ, Ray S, Colice GL. *Clinical Therapeutics*. 2009 12; 31(12): 2779-2803. doi: 10.1016/j.clinthera.2009.12.021.
235. “Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease,” Loftus EV, Jr., Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. *European Journal of Gastroenterology and Hepatology*. 2009 11; 21(11): 1302-1309. doi: 10.1097/MEG.0b013e32832a8d71.
236. “Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors,” Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. *Current Medical Research and Opinion*. 2009 11; 25(11): 2703-2709. doi: 10.1185/03007990903307755.
237. “Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohn's Disease,” Rubin D, Ghosh S, Bensimon A, Yu A, Wu E, Pollack P, Chao J, Mulani P. *American Journal of Gastroenterology*. 2009 10; 104: S464-S465.
238. “Economic burden of psoriasis compared to the general population and stratified by disease severity,” Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Current Medical Research and Opinion*. 2009 10; 25(10): 2429-2438. doi: 10.1185/03007990903185557.
239. “Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy,” Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. *Journal of Medical Economics*. 2009 10; 12(4): 348-355. doi: 10.3111/13696990903378680.
240. “Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease,” Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM. *Pharmacoeconomics*. 2009 08; 27(7): 609-621. doi: 10.2165/11312710-000000000-00000.
241. “Treatment patterns and symptom control in patients with GERD: US community-based survey,” Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M. *Current Medical Research and Opinion*. 2009 08; 25(8): 1869-1878. doi: 10.1185/03007990903035745.
242. “Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs,” Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. *Journal of Medical Economics*. 2009 06; 12(2): 124-135. doi: 10.3111/13696990903093537.
243. “Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia,” Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bollu V. *Journal of Clinical Oncology (Meeting Abstracts)*. 2009 05; 27(15S): 7092.

244. "Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial," Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. *American Journal of Gastroenterology*. 2009 05; 104(5): 1170-1179. doi: 10.1038/ajg.2009.59.
245. "Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?" Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. *Journal of Rheumatology*. 2009 05; 36(5): 1032-1040. doi: 10.3899/jrheum.080487.
246. "Antidepressant treatment patterns and costs among US employees," Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R. *Journal of Medical Economics*. 2009 03; 12(1): 36-45. doi: 10.3111/13696990902757389.
247. "Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial," Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, Pollack PF, Jingdong C, Mulani P. *The American Journal of Gastroenterology*. 2009 104(7).
248. "Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial," Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. *American Journal of Gastroenterology*. 2008 12; 103(12): 3132-3141. doi: 10.1111/j.1572-0241.2008.02175.x.
249. "Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population," Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. *Current Medical Research and Opinion*. 2008 12; 24(12): 3493-3501. doi: 10.1185/03007990802551057.
250. "Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study," Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Jr., Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. *Gastroenterology*. 2008 11; 135(5): 1493-1499. doi: 10.1053/j.gastro.2008.07.069.
251. "Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants," Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH. *Current Medical Research and Opinion*. 2008 10; 24(10): 2805-2813. doi: 10.1185/03007990802336780.
252. "Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective". Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. *Value in Health*. 2008 10; 11(5): 820-829. doi: 10.1111/j.1524-4733.2008.00335.x.
253. "Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn's disease," Feagan B, Loftus E, Johnson S, Wu E, Yu A, Chao J, Mulani P. *American Journal of Gastroenterology*. 2008 09; 103: S383-S383.
254. "Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population," Wu E, Greenberg PE, Yang E, Yu A, Erder MH. *Current Medical Research and Opinion*. 2008 09; 24(9): 2587-2595. doi: 10.1185/03007990802303525.

255. “Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis,” Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. *Current Medical Research and Opinion*. 2008 08; 24(8): 2229-2240. doi: 10.1185/03007990802229548.
256. “Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences,” Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. *Circulation*. 2008 07; 118(5): 491-497. doi: 10.1161/CIRCULATIONAHA.107.752006.
257. “Disease-related and all-cause health care costs of elderly patients with gout,” Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E. *Journal of Managed Care Pharmacy*. 2008 03; 14(2): 164-175.
258. “The costs of Crohn’s disease in the United States and other Western countries: a systematic review,” Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. *Current Medical Research and Opinion*. 2008 02; 24(2): 319-328. doi: 10.1185/030079908X260790.
259. “An evaluation of adalimumab on the risk of hospitalization in patients with Crohn’s disease, data from CHARM: O-007,” Feagan B, Panaccione R, Sandborn W, D’Haens G, Schreiber S, Rutgeerts P, Loftus E, Lomax K, Wu E, Mulani P. *Inflammatory Bowel Diseases*. 2008 01; 14: S2-S3.
260. “Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn’s disease,” Wu E, Yu A, Tang J, Atanasov P, Chao J, Mulani P. *Managed Care Interface*. 2008 21: 20-23.
261. “Adalimumab maintenance therapy for patients with Crohn’s Disease is cost effective compared with nonbiologic maintenance therapy: P-0074.” Feagan B, Loftus EJ, Johnson S, Wu E, Yu A, Chao J, Mulani P. *Inflammatory Bowel Diseases*. 2008 12; 14: S33.
262. “Productivity costs associated with cardiometabolic risk factor clusters in the United States,” Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. *Value in Health*. 2007 11; 10(6): 443-450. doi: 10.1111/j.1524-4733.2007.00199.x.
263. “Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France,” Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S. *Current Medical Research and Opinion*. 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
264. “Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies,” Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. *Journal of Managed Care Pharmacy*. 2007 09; 13(7): 561-569.
265. “Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients,” Wu EQ, Mulani P, Farrell MH, Sleep D. *Value in Health*. 2007 09; 10(5): 408-414. doi: 10.1111/j.1524-4733.2007.00195.x.
266. “Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data,” Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A. *Current Medical Research and Opinion*. 2007 09; 23(9): 2157-2169. doi: 10.1185/0300799007X219544.
267. “Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data,” Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. *Current Medical Research and Opinion*. 2007 08; 23(8): 1749-1759. doi: 10.1185/030079907X210615.

268. "Retrospective economic and outcomes analyses using non-US databases: a review," Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H. *Pharmacoeconomics*. 2007 07; 25(7): 563-576.
269. "Use of inhaled corticosteroids and healthcare costs in mild persistent asthma," Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM. *Journal of Asthma*. 2007 07; 44(6): 479-483. doi: 10.1080/02770900701424124.
270. "Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.," Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. *Obesity*. 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.
271. "Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach," Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. *Psychological Medicine*. 2006 11; 36(11): 1535-1540. doi: 10.1017/S0033291706008191.
272. "Annual costs associated with diagnosis of uterine leiomyomata," Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P. *Obstetrics and Gynecology*. 2006 10; 108(4): 930-937. doi: 10.1097/01.AOG.0000234651.41000.58.
273. "Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States," Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. *Stroke*. 2006 10; 37(10): 2567-2572. doi: 10.1161/01.STR.0000240506.34616.10.
274. "Development of a COPD severity score." Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. *Current Medical Research and Opinion*. 2006 09; 22(9): 1679-1687. doi: 10.1185/030079906X115621.
275. "Tighter control of serum uric acid in gout is associated with lower morbidity and health care costs," Wu EQ, Mody RR, Krishnan E, Yu AP, Cahill KE, Tang J, Patel PA. *Arthritis and Rheumatism*. 2006 09; 54(9): S332-S332.
276. "Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population," Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. *Journal of Occupational Environmental Medicine*. 2006 08; 48(8): 794-802. doi: 10.1097/01.jom.0000229819.26852.0e.
277. "Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain," Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S. *Journal of Pain*. 2006 06; 7(6): 399-407. doi: 10.1016/j.jpain.2006.01.443.
278. "Prevalence of diabetic peripheral neuropathy and associated pain in French adults," Wu E, Borton J, Kahn E, Said G, Le T, Garcia-Cebrian A, Monz B. *Journal of Neurology*. 2006 05; 253: 108-108.
279. "A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis," Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ. *Current Medical Research and Opinion*. 2006 03; 22(3): 495-500. doi: 10.1185/030079906X80431.
280. "Comorbidity contributes to high treatment cost of interstitial cystitis," Wu E. *PharmacoEconomics & Outcomes News*. 2006 02; (497): 6.
281. "Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population," Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. *Pharmacoeconomics*. 2006 02; 24(1): 55-65.

282. “Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer’s Perspective,” Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K. *Drug Benefit Trends*. 2006 18(7): 405.
283. “Unemployment drives high cost of schizophrenia in the US,” Wu E. *PharmacoEconomics & Outcomes News*. 2005 12; 493: 17.
284. “Economic burden and co-morbidities of atrial fibrillation in a privately insured population,” Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J. *Current Medical Research and Opinion*. 2005 10; 21(10): 1693-1699. doi: 10.1185/030079905X65475.
285. “The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R),” Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ. *Biological Psychiatry*. 2005 10; 58(8): 668-676. doi: 10.1016/j.biopsych.2005.04.034.
286. “The economic burden of schizophrenia in the United States in 2002,” Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. *Journal of Clinical Psychiatry*. 2005 09; 66(9): 1122-1129.
287. “Costs of schizophrenia have shifted,” Wu E. *PharmacoEconomics & Outcomes News*. 2005 06; 480: 18.
288. “Employees with overactive bladder: work loss burden,” Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. *Journal of Occupational Environmental Medicine*. 2005 05; 47(5): 439-446.
289. “PUK9 Interstitial Cystitis Costs, Treatment and Comorbidities in an Employed Population,” Wu EQ, Birnbaum H, Parece A, Kang YJ, Mareva MN, Taitel H. *Value in Health*. 2005 8(3): 415-416. doi: 10.1016/S1098-3015(10)63135-X.

Book Chapter

1. “China’s Urban Health Insurance Reform Experiment In Zhenjiang: Cost And Utilization Analyses,” Liu G, Cai R, Chao S, Xiong X, Zhao Z, Wu EQ, in *The Economics of Health Care in Asia-Pacific Countries*, Edward Elgar Publishing Limited, 2002: 143.

SELECTED CONFERENCE PRESENTATIONS

1. Epidemiology, treatment patterns, and healthcare resource utilization in patients with acute myeloid leukemia in China: A retrospective observational study. Cheng LJ, Gong B, Young C, Krishnana P, Wang Y, Wei H, Zhou C, Wei S, Li Y, Fang Q, Zhong J, Wu E, Mi Y, Wang J. 17th Biennial of the National Conference on Hematology of the Chinese Medical Association, Shanghai, China, September 23–25, 2022.
2. A Retrospective Database Analysis Study to Evaluate Disease Burden and Treatment Patterns among Patients with Hemophilia A in China. Song X, Liu W, Xue F, Yang Y, Sun S, Zhong J, Liu Y, Shi J, Zhang L, Wu E, Yang R. International Society on Thrombosis and Haemostasis (ISTH), London, UK, July 9–13, 2022.

3. Real-world Outcomes of Onasemnogene Abeparvovec Alone or With Prior Nusinersen in Pediatric SMA: Interim Analysis of a US Chart Review. Dabbous O, Yang M, Georgieva M, Toro W, LaMarca N, Patel A, Minkoff N, Carley C, Zhu J, Anderson A, Wu E. World Muscle Society (WMS) 2021 Virtual Congress, September 20–24, 2021.
4. Health care resource utilization in pediatric patients with spinal muscular atrophy: Interim analysis of a US retrospective chart review study. Dabbous O, Yang M, Georgieva M, Toro W, LaMarca N, Patel A, Minkoff N, Carley C, Zhu J, Anderson A, Wu E. WMS 2021 Virtual Congress, September 20–24, 2021.
5. Migraine-related healthcare resource use and costs associated with migraine chronification: a panel-based chart review. Vo P, Swallow E, Wu E, Ellis M, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Joshi P, Ferraris M. 7th Congress of the European Academy of Neurology (virtual), June 19–22, 2021.
6. Cost of Chronic Myeloid Leukemia Care Among Patients in Advanced Phases or on Later Lines of Therapy in Chronic Phase in the United States from a Commercial and Medicare Perspective. Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. 2021 Virtual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 17–20, 2021.
7. Real World Treatment Patterns of Patients with Ovarian Cancer – Analysis of Targeted Therapies in the French National Claims Data. Wu E, Ben-Hamadi R, Jenkins M, Duberga J, Lopez J, Viola M, Zhou J. 2021 Virtual ISPOR Annual Meeting, May 17–20, 2021.
8. Outcomes of single-agent onasemnogene abeparvovec or nusinersen, and of nusinersen switching to onasemnogene abeparvovec, in patients with spinal muscular atrophy: Results of a provider survey in the United States. Yang M, Georgieva M, Wu E, Dabbous O, LaMarca N, Shenouda L, Patel A, Toro W, Bischof M, Minkoff N. American Academy of Neurology Virtual Annual Meeting, April 17–22, 2021.
9. Healthcare resource utilization and costs among patients with EGFR mutated metastatic NSCLC who have discontinued EGFR-TKI and platinum-based chemotherapy regimens. Marrett E, Kwong WJ, Xie J, Manceur A, Sendhil S, Wu E, Ionescu-Ittu R. AMCP 2021 Virtual Annual Meeting, April 12–16, 2021.
10. Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy: A SEER-Medicare Analysis. Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. AMCP 2021 Virtual Annual Meeting, April 12–16, 2021.
11. Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States. Arjunji R, Zhou J, Patel A, Edwards ML, Harvey M, Wu E, Dabbous O. AMCP Nexus 2020, November 19–21, 2020.
12. Outcomes of Pediatric Patients with Spinal Muscular Atrophy (SMA) Treated with Onasemnogene Abeparvovec: Results of a Provider Survey in the United States. Dabbous O, Yang M, LaMarca N, Wu E, Patel A, N. M, Toro W, Bischof M, Droege M, Wolff D, Georgieva M, Reyna S. ISPOR Europe 2020 Virtual Conference, November 14–18, 2020.
13. Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache

- centers. Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Hogan R, Blumenfeld AM, Schim J, Feoktistov A, Carnes K, Bensink ME, Wu EQ, Chou DE, Chandler D. Migraine Trust Virtual Symposium 2020, October 3–9, 2020.
14. Real-world clinical outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents in the US: A SEER-Medicare analysis. Stein EM, Latremouille-Viau D, Shi S, Guérin A, Wu EQ, Bonifacio G, Cao X. European Hematology Association, Frankfurt, Germany, June 11–14, 2020.
 15. Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis. Stein E, Latremouille-Viau D, Shi S, Guerin A, Wu E, Bonifacio G, Cao X. ISPOR 2020 Virtual Conference, May 18–20, 2020.
 16. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis. Stein E, Latremouille-Viau D, Joseph G, Shi S, Guerin A, Wu E, Bonifacio G, Cao XY. ASH 2019 Conference Orlando, FL, December 7–10. 2019.
 17. Dupilumab improves outcomes in patients with atopic dermatitis (AD) in clinical practice – Results from the RELIEVE-AD study. Strober B, Mallya UG, Yang M, Gadkari A, Boklage S, Fenton M, Chamberlain CX, Sierka D, Wu EQ, Kimball AB. European Academy of Dermatology and Venereology (EADV) 28th Congress, Madrid, Spain, October 9–13, 2019.
 18. Dupilumab improves treatment satisfaction and reduces treatment burden in adults with atopic dermatitis: Results from the RELIEVE-AD study. Kimball AB, Mallya UG, Yang M, Gadkari A, Boklage S, Fenton M, Chamberlain CX, Sierka D, Wu EQ, Strober BE. European Academy of Dermatology and Venereology (EADV) 28th Congress, Madrid, Spain, October 9–13, 2019.
 19. Treatment Patterns, Healthcare Resource Use, and Outcomes of Patients with Chronic and Episodic Migraines Treated with Erenumab: A Multicenter Chart-Review Study. Faust E, Pivneva I, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Feoktistov A, Bensink M, Wu EQ, Chandler D. 61st Annual Scientific Meeting of the American Headache Society, Philadelphia, PA, July 11–14, 2019.
 20. Management, Post-Discharge Admission, and Recurrence among Hyperkalemic Patients in the Emergency Department Setting. Davis J, Israni R, Betts KA, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Wu E. NKF 2019 Spring Clinical Meeting, Boston, MA, May 8–12, 2019.
 21. PMU87: Matching Adjusted Indirect Comparisons: Recommendation for the Selection of Baseline Characteristics Used for Matching. Gao W, Patterson-Lomba O, Signorovitch J, Wu EQ, Ayyagari R. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA, May 18–22, 2019.
 22. RO2: Assessing the Relationship between Lifelong Value and Pricing for Orphan Drugs in Ultra-Rare Diseases. Dabbous O, Zhou ZY, Tang C, Harvey M, Wu EQ, Arjunji R. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA, May 18–22, 2019.
 23. PNS196: Use of Machine Learning in Health Economics and Outcomes Research (Heor): Optimizing Predictive Models. Royer J, Wu E, Ayyagari R. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA, May 18–22, 2019.

24. Management of Hyperkalemic Patients in the Inpatient Setting by Hyperkalemia Severity. Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Fonseca V, Wu E. AMCP's 31st Annual Meeting, San Diego, CA, Mar 25–28, 2019.
25. An Application of Artificial Intelligence-Based Methodology in Literature Reviews. Wu EQ, Ayyagari R, Royer J, Li J, Wang J, Lefebvre P, Patterson-Lomba O. ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain, Nov 10–14, 2018.
26. Artificial Intelligence Assisted Literature Reviews: Key Considerations for Implementation in Health Care Research. Wu EQ, Royer J, Ayyagari R, Signorovitch J, Thokala P. ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain, Nov 10–14, 2018.
27. Number needed to treat in patients with spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen. Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Droege M, Sproule DM. AMCP Nexus 2018, Orlando, FL, Oct 22–25, 2018.
28. Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1. Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM. 23rd International Annual Congress of the World Muscle Society, Mendoza, Argentina, Oct 2–6, 2018.
29. Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective. Lin FI-I, R; Pivneva, I; Wynant, W; Shi, S; Shohudi Mojdehi, A; Wu, E.Q; Kwong, J; Abraham, J.A. ASCO Quality Care Symposium, Phoenix, AZ, Sept 28–29, 2018.
30. Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis. Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Huang X, Skup M, Elewski B. European Academy of Dermatology and Venereology, Paris, France, Sep 12–16, 2018.
31. Patient-Reported Outcomes from the IMMVent Trial: Comparison of Risankizumab with Adalimumab in Moderate to Severe Psoriasis Patients. Crowley J, Skup M, Huang X, Yang M, Wu EQ, Thompson E, Zema C, Reich K. European Academy of Dermatology and Venereology, Paris, France, Sep 12–16, 2018.
32. Risankizumab Significantly Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis in Two Phase III UltIMMa Trials. Augustin M, Lambert J, Zema C, Thompson E, Yang M, Wu EQ, Geng Z, Valdes J, Skup M, Gordon M. European Academy of Dermatology and Venereology, Paris, France, Sept 12–16, 2018.
33. Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1 Treated with AVXS-101 Relative to Nusinersen. Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu E, Sproul D. 15th International Congress on Neuromuscular Diseases, Vienna, Austria, Jul 6–10, 2018.
34. Economic impact of non-medical switching from originator biologics to biosimilars—a systematic literature review. Liu Y, Garg V, Yang M, Wu EQ, Skup M. Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands, Jun 13–16, 2018.
35. Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective. Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Mojdehi AS, Wu E, Kwong J, Abraham JA. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, Jun 15, 2018.

36. Healthcare costs associated with hyperprolactinemia in the United States. Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrín P, Wu EQ. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19–23, 2018.
37. Number needed to treat in patients with spinal muscular atrophy type 1 treated with AVXS-101 relative to nusinersen. Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19–23, 2018.
38. Reduced risk of hyperprolactinemia among patients treated with atypical antipsychotics that are associated with low or no prolactin elevation. Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrín P, Wu EQ. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19–23, 2018.
39. Surrogate Outcomes in Oncology: How can they be used to predict overall survival in clinical practice and payer decision making? Ayyagari R, Xie J, Wu E, Song J. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19–23, 2018.
40. Real-world use of faecal calprotectin testing in patients with inflammatory bowel disease. Rubin DT, Yang M, Wu EQ, Skup M, Lee WJ. 13th Congress of European Crohn's and Colitis Organisation, Vienna, Austria, Feb 14–17, 2018.
41. Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210. Vander Velde NS, Guerin A, Ionescu-Ittu R, Shi S, Wu E, Lin SW, Hsu LI, Saum KU, Ducla SD, Wang J, Li S, Derleth CL, Liu S, Shi L, Leppert J. Genitourinary Cancers Symposium, San Francisco, CA, Jan 18–20, 2018.
42. Patient preferences in advanced soft tissue sarcoma: A discrete choice experiment. Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J. The Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting, Maui, HI Nov 8–11, 2017.
43. Overall survival in patients with metastatic urothelial cancer by first-line therapy. Vander Velde NS, Guerin A, Ionescu-Ittu R, Shi S, Wu E, Lin S, De Ducla S, Wang J, Li S, Derleth C, Leppert JT, Liu S, Shi L. ISPOR 20th Annual European Congress, Glasgow, UK, Nov 4–8, 2017.
44. Patient characteristics of premix insulin users in china: An analysis of electronic medical record data. Han S, Wang K, Hou J, Wang J, Wu EQ. ISPOR 20th Annual European Congress, Glasgow, UK, Nov 4–8, 2017.
45. Development of a predictive model for hyperkalemia. Betts K, Woolley JM, Mu F, Bocharova I, Bensimon AG, Wu E. American Society of Nephrology Kidney Week, Oct. 31–Nov. 5, 2017.
46. Economic burden of hyperkalemia in the Medicare system. Betts K, Woolley JM, Mu F, Xiang CQ, Dua A, Wu E. American Society of Nephrology Kidney Week, Oct. 31–Nov. 5, 2017.
47. Indirect comparison of sodium zirconium cyclosilicate versus patiromer in the treatment of hyperkalemia through 48 hours. Betts K, Woolley JM, Song Y, Gao W, Wu E. American Society of Nephrology Kidney Week, Oct. 31–Nov. 5, 2017.
48. Post-discharge economic burden of hyperkalemia-related hospitalizations. Betts K, Woolley JM, Mu F, Kelkar SS, Xiang CQ, Wang Y, Wu E. American Society of Nephrology Kidney Week, Oct. 31–Nov. 5, 2017.

49. Prevalence of Hyperkalemia in Medicare Patients. Betts K, Woolley J, Mu F, Tang W, Wang Y, Wu E. American Society of Nephrology Kidney Week, Oct. 31–Nov. 5, 2017.
50. Assessing patient preferences for and relative importance of features of new direct acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infections. Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ. 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, Oct 20–24, 2017.
51. Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD). Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J. Society for Investigative Dermatology (SID) 2017 Annual Meeting, Portland, OR, Apr 26–29, 2017.
52. The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: Real-world evidence from the United States. Reau N, Vekeman F, Wu E, Bao C, Gonzalez YS. International Liver Congress 2017: 52nd Annual Meeting of the European Association for the Study of the Liver, Amsterdam, Netherlands, Apr 19–23, 2017.
53. Cost of hyperkalemia among patients with heart failure. Woolley JM, Betts K, Mu F, Xiang C, Tang W, Wu E. American Heart Association’s 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA, Nov 12–14, 2016.
54. Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP). Han S, Xie J, Song H, Zhang C, Wu EQ. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29–Nov 2, 2016.
55. Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in china: An analysis of electronic medical record data. Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29 –Nov 2, 2016.
56. Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data. Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29–Nov 2, 2016.
57. Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. 141st Annual Meeting of the American Neurological Association, Baltimore, MD, Oct 16–18, 2016.
58. Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC). Yim YM, Gandhi M, Guerin A, Ionescu-Ittu R, Pivneva I, Shi S, Wu E. 41st European Society for Medical Oncology Congress, Copenhagen, Denmark, Oct 7–11, 2016.
59. The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E. AMCP Nexus 2016, Baltimore, MD, Oct 3–6, 2016.

60. The Prevalence of Hyperkalemia in the United States. Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhania A, Pham H, Hollenack K, Wu EQ. AMCP Nexus 2016, Baltimore, MD, Oct 3–6, 2016.
61. Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US. Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R. 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany, Sept 12–16, 2016.
62. The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US. Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R. 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany, Sept 12–16, 2016.
63. Economic burden of relapsed/refractory chronic lymphocytic leukemia". Guerin A, Ray S, Gauthier G, Hsu LI, Zhdanova M, Heroux J, Wu E. 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, Australia, Sept 6–9, 2015.
64. Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: an analysis of electronic medical record data. Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ. ISPOR 7th Asia-Pacific Conference, Singapore, Sep 3–6, 2016.
65. Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data. Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ. ISPOR 7th Asia-Pacific Conference, Singapore, Sep 3–6, 2016.
66. Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis. Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N HY, Xie J, Lin PL, Ohashi E, Koo V, Wu EQ, Zhao J, Koo V, Wu E. American Society for Microbiology (ASM) 2016, Boston, MA, Jun 16–20, 2016.
67. Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study. Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Tsai C, Bao Y, Skup M, Yang M, Wu EQ, wGarg V. European League Against Rheumatism Congress, London, UK, Jun 8–11, 2016.
68. Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel. Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL. ASCO Annual Meeting, Chicago, IL, Jun 3–7, 2016.
69. Assessment of the real-world safety profile of vedolizumab using the united states food and drug administration adverse event reporting system (FAERS). Cross R, Vekeman F, Xiao Y, Wu EQ, Chao J, Wang A. Digestive Disease Week, San Diego, CA, May 21–24, 2016.
70. Comorbidities and symptoms among endometriosis patients: A systematic literature review. Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C. ISPOR 21st Annual International Meeting, Washington, DC, May 21–25, 2016.

71. Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the United States. Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C. ISPOR 21st Annual International Meeting, Washington, DC, May 21–25, 2016.
72. Real-world costs of ischemic stroke by discharge status. Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ. ISPOR 21st Annual International Meeting, Washington, DC, May 21–25, 2016.
73. Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters. Vazquez B, Hesdorffer D, Wu E, Macaulay D, Sorg R, Squillacote D, Sidovar M, Guo A. AMCP's 28th Annual Meeting, San Francisco, CA, Apr 19–22, 2016.
74. Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis. Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A. 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Apr 15–21, 2016.
75. Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis. Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J. 74th Annual Meeting of the American Academy of Dermatology, Washington, DC, Mar 4–8, 2016.
76. Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis. Armstrong A, Betts K, Sundaram M, Li J, Wu E. 74th Annual Meeting of the American Academy of Dermatology, Washington, DC, Mar 4–8, 2016.
77. A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond. Gauthier G, Guerin A, Zhdanava M, Wu E. San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 8–12, 2015.
78. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites. Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E. 2015 San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 8–12, 2015.
79. Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with liver metastasis or multiple metastatic sites. Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J. 2015 San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 8–12, 2015.
80. What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine? Cloutier M, Guerin A, Heroux J, Emond B, Wu E. 2015 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–12, 2015.
81. Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from US payers' perspective. Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L. 57th Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 5–8, 2015.
82. The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients. Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanava M, Wu E. 57th Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 5–8, 2015.

83. Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients. Guerin A, Ray S, Gauthier G, Hsu Ling-I, Zhdanava M, Wu EQ. 57th Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 5–8, 2015.
84. Comorbidity burden and medication use among patients with psoriatic arthritis in the US. Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB. American College of Rheumatology Annual Scientific Meeting, San Francisco, CA, Nov 6–11, 2015.
85. Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in the U.S. and EU-5: Payer and manufacturer experience and outlook. Ko J, Nazareth T, Carpenter S, Demean S, Wu E, Sasane R, Navarro R. AMCP Nexus 2015, Orlando, FL, Oct 26–29, 2015.
86. Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC). Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A. 16th World Conference on Lung Cancer, Denver, CO, Sep 6–9, 2015.
87. Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/ refractory Hodgkin lymphoma post-autologous stem cell transplant. Bonthapally V, Yang H, Ayyagari R, Tan R, Cai S, Wu E, Gautam A, Chi A, Huebner D. 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, Jun 17–20, 2015.
88. Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. 2015 ASCO Annual Meeting, Chicago, IL, May 29–Jun 2, 2015.
89. Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ. 2015 ASCO Annual Meeting, Chicago, IL, May 29–Jun 2, 2015.
90. Economic burden of relapsed/refractory chronic lymphocytic leukemia. Guerin A, Ray S, Gauthier G, Hsu L, Zhdanava M, Heroux J, Wu EQ. ASCO Annual Meeting, Chicago, IL, May 29–Jun 2, 2015.
91. Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer. Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015.
92. Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review. Vazquez B, Sidovar M, Squillacote D, Wu E, Macaulay D, Sorg R, Guo A. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015.
93. Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook. Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015.
94. Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer. Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR,

- Ohashi E, Zhou Z, Wu EQ. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015.
95. Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US. Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C. ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015.
 96. Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US. Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ. AMCP's 27th Annual Meeting, San Diego, CA, Apr 7–10, 2015.
 97. Economic consequences of cytomegalovirus disease among stem cell transplant recipients. Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR. 2015 BMT Tandem Meetings, San Diego, CA, Feb 11–15, 2015.
 98. Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis. Vazquez B, Wu E, Macaulay D, Sidovar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A. 68th Annual Meeting of the American Epilepsy Society, Seattle, WA, Dec 5–9, 2014.
 99. Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy. Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L. American Society of Hematology, San Francisco, CA, Dec 6–9, 2014.
 100. Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy. Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L. American Society of Hematology, San Francisco, CA, Dec 6–9, 2014.
 101. Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer. Gallagher CM, More KF, Sicignano N, Masaquel A, Barnett B, Kamath T, Guérin A, Ionescu-Ittu R, Gauthier-Louiselle M, Nitulescu R, Wu EQ. 2014 San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 9–13, 2014.
 102. The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs. Velez F, Bollu V, M. C, Guerin A, Carter V, Heroux J, Nitulescu R, Wu EQ. 2013 Annual Meeting of the American Epilepsy Society, Washington, DC, Dec 6–10, 2013.
 103. Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis. Bollu V, Velez F, Cloutier M, Guerin A, Carter V, Heroux J, Dea K, Wu EQ. 2013 Annual Meeting of the American Epilepsy Society, Washington, DC, Dec 6–10, 2013.
 104. A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib. Smith BD, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandez D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir CH, Chen L. 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, Dec 6–9, 2014.

105. Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP). Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L. 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, Dec 6–9, 2014.
106. Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC. Macalalad A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu E, Guerin A. 19th Annual Scientific Meeting of the Society for Neuro-Oncology Conference, Miami, FL, Nov 13–16, 2014.
107. Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the US department of defense practice setting. Gallagher CM, More K, Masaquel AS, Kamath T, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Barnett B, Wu EQ. ISPOR 17th Annual European Congress, Amsterdam, Netherlands, Nov 8–12, 2014.
108. Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. ISPOR 17th Annual European Congress, Amsterdam, Netherlands, Nov 8–12, 2014.
109. Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data. Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L. ISPOR 17th Annual European Congress, Amsterdam, Netherlands, Nov 8–12, 2014.
110. Description of ALK+ NSCLC patient characteristics and ALK testing patterns. Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Guerin A. 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology Chicago, IL, Oct 30–Nov 1, 2014.
111. Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients. Guerin A, Sasane M, Zhang J, Culver K, Macalalad A, Nitulescu R, Wu E, Dea K. 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, Oct 30–Nov 01, 2014.
112. A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients. Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C. 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI, Oct 18–22, 2014.
113. Treatment patterns among US women diagnosed with endometriosis: A retrospective claims analyses pre-and post-diagnosis. Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C. 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI, Oct 18–22, 2014.
114. Age-related health care disparities in patients with irritable bowel syndrome: Findings from a sample of commercially insured patients. Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopel J, Mody R. 79th Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA, Oct 17–22, 2014.
115. Regional variation of care for irritable bowel syndrome in the United States. Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopel J, Mody R. 79th Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA, Oct 17–22, 2014.

116. Healthcare resource utilization preceding first diagnosis for fragile x syndrome (fxs). Nazareth T, Marynchenko M, Chopra P, Li N, Zhou Z, Signorovitch J, Wu E, Marvel J, Ahmed S, Sasane R. ANA 2014 Annual Meeting, Baltimore, MD, Oct 12–14, 2014.
117. Medical specialists involved in caring for patients with fragile x syndrome (FXS): a Medicaid perspective. Nazareth T, Marynchenko M, Li N, Chopra P, Zhou Z, Signorovitch J, Wu EQ, Ahmed S MJ, Sasane R. ANA 2014 Annual Meeting, Baltimore, MD, Oct 12–14, 2014.
118. Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers. Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ. AMCP Nexus 2014, Boston, MA, Oct 7–10, 2014.
119. Economic burden of brain metastases among lung cancer patients. Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A. AMCP Nexus 2014, Boston, MA, Oct 7–10, 2014.
120. Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors. Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu EQ, Conley AP. 2014 European Society for Medical Oncology Congress, Madrid, Spain, Sep 26–30, 2014.
121. Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting. Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A. 2014 European Society for Medical Oncology Congress, Madrid, Spain, Sep 26–30, 2014.
122. Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients. Yang H, Zhuo D, Zhou Z, Wu EQ, Chaudhari P, Snyderman DR. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Sep 5–9, 2014.
123. Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. ISPOR 6th Annual Asia-Pacific Conference, Beijing, China, Sep 6–9, 2014.
124. Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis. Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA. 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL, Jun 21–24, 2014.
125. Systematic Review of real-world evidence on treatment of Acromegaly. Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Alaghband R, Wu EQ. 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL, Jun 21–24, 2014.
126. Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension. Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ. American Association of Nurse Practitioners 2014 National Conference, Nashville, TN, Jun 17–22, 2014.
127. Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review. Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O. 19th Congress of the European Hematology Association, Milan, Italy, Jun 12–15, 2014.

128. Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C. Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
129. Identifying high-value treatment populations in clinical trials and real-world data. Signorovitch J, Shaw J, Betts K, Wu EQ. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
130. Costs of venous thromboembolism (VTE) among hospitalized patients in China. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
131. Treatment and survival patterns among ALK+NSCLC patients following crizotinib discontinuation. Guerin A, Wakelee H, Sasane M, Zhang J, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Macalalad AR. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
132. Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis C infection. Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
133. Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC). Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ. ISPOR 19th Annual International Meeting, Montreal, QC, May 31–Jun 4, 2014.
134. Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices. Lin PL, Macalalad AR, Hao Y, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
135. Description of ALK+ NSCLC patient characteristics and ALK testing patterns. Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach PJ, Jarvis J, Kageleiry AJ, Huang Q, Culver KW, Wu EQ, Guerin A. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
136. Impact of underestimation of risk on treatment duration and recurrence in GIST patients. Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 2014.
137. One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison. Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ. ASCO 50th Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
138. Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice. Hao Y, Lin PL, Macalalad AR, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.

139. Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States. Wu EQ, Hao Y, Signorovitch JE, Lin PL, Macalalad AR, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
140. Prescribing and monitoring patterns for HR+/HER2- advanced breast cancer: A survey of community-based oncologists. Lin PL, Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
141. Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer. Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Wu EQ, Sicignano N, Butts E, Barnett B. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
142. Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC. Guerin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu EQ, Macalalad AR. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
143. Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
144. Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices. Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Lin PL, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA. 2014 ASCO Annual Meeting, Chicago, IL, May 30–Jun 3, 2014.
145. Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective. Signorovitch J, Wu E, Li N, Chopra P. APA 167th Annual Meeting, New York, NY, May 3–7, 2014.
146. Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective. Signorovitch J, Wu E, Li N, Chopra P. APA 167th Annual Meeting, New York, NY, May 3–7, 2014.
147. Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer. Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
148. Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer. Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
149. Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook. Frois C, Carpenter S, Demean S, Wu E, Navarro R. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
150. Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic

- breast cancer. Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
151. Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
 152. Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer in the US. Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. AMCP's 26th Annual Meeting, Tampa, FL, Apr 1–4, 2014.
 153. Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors. Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, Wu E. NCCN 19th Annual Conference, Hollywood, FL, Mar 13–15, 2014.
 154. Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors. Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ. 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, Jan 16–18, 2014.
 155. Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+ CML-CP) from the enestnd trial: 48-month follow-up. Chen L, Guerin A, Marynchenko M, Ionescu-Ittu R, Hiscock R, Nitulescu R, Pooja C, Hsu LI, Keir C, Wu EQ. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec 7–10, 2013.
 156. Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in the United Kingdom. Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov 2–6, 2013.
 157. Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review. Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov 2–6, 2013.
 158. Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis. Wu EQ, Cifaldi M, Diener M, Kaltenboeck A, Ganguli A, Bergman M. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov 2–6, 2013.
 159. Overall survival and hospitalization rates in Medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study. Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-Ittu R, Wu EQ, Ramalingam SS. 15th World Conference on Lung Cancer, Sydney, Australia, Oct 27–30, 2013.
 160. Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope. Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Wu EQ. 15th World Conference on Lung Cancer, Sydney, NSW Australia, Oct 27–30, 2013.
 161. Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL. 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM, Oct 13–16, 2013.

162. Antitumor activity of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT): Meta-analysis comparison. Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D. 9th International Symposium on Hodgkin Lymphoma Conference, Cologne, Germany, Oct 12–15, 2013.
163. Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors. Guerin A, Mody R, Carter V, Wu E. 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11–16, 2013.
164. Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis. Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E. 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain, Sep 23–27, 2013.
165. Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis. Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Lopez C, Viswanathan P, Wu E. 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain, Sep 23–27, 2013.
166. Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010. Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Aug 25–28, 2013.
167. Vitala™ Continence Control Device vs. Traditional Pouch System: A Comparison of Health-Related Quality-of-Life. Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J. 12th European Council of Enterostomal Therapy Congress, Paris, France, Jun 23–26, 2013.
168. Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM). Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ. 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, Jun 21–25, 2013.
169. Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge. Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ. COPD8USA Conference, Chicago, IL, Jun 14–15, 2013.
170. Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab. Lalla D, Brammer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E. 2013 ASCO Annual Meeting, Chicago, IL, Jun 4, 2013.
171. Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ. 2013 ASCO Annual Meeting, Chicago, IL, May 31–Jun 4, 2013.
172. Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting. Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E. 2013 ASCO Annual Meeting, Chicago, IL, May 31–Jun 4, 2013.

173. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML). Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL. 2013 ASCO Annual Meeting, Chicago, IL, May 31–Jun 4, 2013.
174. Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach. Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. 2013 ASCO Annual Meeting, Chicago, IL, May 31–Jun 4, 2013.
175. Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach. Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. 2013 ASCO Annual Meeting, Chicago, IL, May 31–Jun 4, 2013.
176. Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio. Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.
177. Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients. Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.
178. Economic Outcomes Associated with Hba1c and Ldl-C Goal Achievement In Patients with Type 2 Diabetes Mellitu. Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V. ISPOR18th Annual International Meeting, May 18–22, 2013.
179. Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis. Kan H, Guerin A, Kaminsky M, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta CT. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.
180. Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder. De G, Yang H, Runken M, Yan Y, Kelkar S, Bui C, Xie J, Wu E. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.
181. Matching-adjusted indirect comparisons: A simulation study of statistical performance. Signorovitch J, Ayyagari R, Cheng D, Wu E. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.
182. Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists. Bollu V, Guerin A, Karafilidis J, Gauthier G, Hiscock R, Wu E. American Thoracic Society International Conference, Philadelphia, PA, May 17–22, 2013.
183. Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm. Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ. Digestive Disease Week, Orlando, FL, May 18–21, 2013.
184. Trend in economic burden of diabetes in urban china from 2009 to 2011. Wu E, Xie J, Du E, Liu M, Liu G. ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013.

185. Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation. Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ. American Heart Association's Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD, May 15–17, 2013.
186. Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer. Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E. AMCP's 25th Annual Meeting, San Diego, CA, Apr 3–5, 2013.
187. Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population. Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ. AMCP's 25th Annual Meeting, San Diego, CA, Apr 3–5, 2013.
188. Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA. American Heart Association's Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism 2013 Scientific Sessions, New Orleans, LA, Mar 3–22, 2013.
189. An economic model of improved acute stroke care in the management of acute ischemic stroke from a state Medicaid perspective. Zhou ZY, Fan L, Chen E, Xie J, Wu EQ. 2013 International Stroke Conference and Nursing Symposium of the American Heart Association/American Stroke Association, Honolulu, HI, Feb 6–8, 2013.
190. Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis. DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec 8–11, 2012.
191. Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy. Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec 8–11, 2012.
192. Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy. Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec 8–11, 2012.
193. Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey. Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec 8–11, 2012.
194. Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy. Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec 8–11, 2012.
195. Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States. Xie J, Diener M,

- De G, Yang H, Wu EQ, Namjoshi M. 35th Annual CTSC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 4–8, 2012.
196. Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; A retrospective analysis. Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D. 35th Annual CTSC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 4–8, 2012.
 197. Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. ASCO's Quality Care Symposium, San Diego, CA, Nov 30–Dec 1, 2012.
 198. Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone. Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC, Nov 9–14, 2012.
 199. Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept. Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC, Nov 9–14, 2012.
 200. Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone. Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC, Nov 9–14, 2012.
 201. Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first and second-line chemotherapies. Hurvitz SA, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D. ISPOR 15th Annual European Congress, Berlin, Germany, Nov 3–7, 2012.
 202. Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States. Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ. ISPOR 15th Annual European Congress, Berlin, Germany, Nov 3–7, 2012.
 203. HbA1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM). Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ. ISPOR 15th Annual European Congress, Berlin, Germany, Nov 3–7, 2012.
 204. Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review. Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S. Canadian Hypertension Congress, Toronto, Canada, Oct 25–28, 2012.
 205. Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.

- Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W. 59th AACAP Annual Meeting, San Francisco, CA, Oct 23–28, 2012.
206. Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom. Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM. 20th United European Gastroenterology Week, Amsterdam, Netherlands, Oct 20–24, 2012.
207. A validated claims-based prediction model for COPD severity. Macaulay D, Sun S, Sorg R, Yan S, De G, Wu E, Simonelli P. CHEST 2012 Atlanta, GA, Oct 20–25, 2012.
208. Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective. Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E. 26th Annual North American Cystic Fibrosis Conference, Orlando, FL, Oct 11–13, 2012.
209. Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation. Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley N. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV, Oct 19–24, 2012.
210. Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation. Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley NJ. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV, Oct 19–24, 2012.
211. Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation. Mody R, Guerin A, Fok B, Zhou Z, Wu E, Brewer K, Zhou W, Lasch K, Talley N. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV, Oct 19–24, 2012.
212. Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis in the US. Ali T, Skup M, Yang M, Wu E, Mulani P, Chao J. 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV, Oct 19–24, 2012.
213. A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics. Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH. Institute of Psychiatric Services Meeting, New York, NY, Oct 4–7, 2012.
214. Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide. Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J. AMCP's 2012 Educational Conference, Cincinnati, OH, Oct 3–5, 2012.
215. Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide. Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ. AMCP's 2012 Educational Conference, Cincinnati, OH, Oct 3–5, 2012.
216. Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus. Chen K, Wu E, Cheng D, Bensimon A, Bron M. 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, Oct 2–5, 2012.

217. Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate. Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM. 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, Sep 27–30, 2012.
218. Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP). Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L. ESH-iCML International Conference, Baltimore, MD, Sep 20–23, 2012.
219. PDB17 Comparison of Clinical and Economic Outcomes Associated with Dpp4 Inhibitors (DPP4I) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM). Bron M, Chen K, Cheng D, Bensimon A, Wu E. ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, Sep 2–4, 2012.
220. Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis. Chen K, Bron M, Cheng D, Sharma H, Wu EQ. ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, Sep 2–4, 2012.
221. Glycemic control and quality of life for patients with type 2 diabetes mellitus in China. Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ. ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, Sep 2–4, 2012.
222. Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis. Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH. 20th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Paris, France, Jul 21–25, 2012.
223. Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first-and second-line chemotherapies. Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky M, Wu EQ, Lalla D. 2012 International MASCC/ISOO Symposium: Supportive Care in Cancer, New York, NY, Jun 28–30 2012.
224. Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China. Yang HY, Wu J, Zheng Y, Xie K, Jin L, Xie J, Wu EQ. ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.
225. Economic burden of hepatocellular carcinoma in China. Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J. ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.
226. Economic burden of type 2 diabetes mellitus in China. Zheng Y, Wu EQ, Xie K, Zheng B, Yang HY, Xie J, Wu J. ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.
227. The economic burden of unmet treatment needs in Medicaid patients with chronic constipation. Carson RT, Guerin A, Lewis B, Yin D, Kaminsky M, Ramakrishnan K, Wu EQ. ISPOR 17th Annual International Meeting, Washington, DC, Jun 2–6, 2012.
228. Health utility for patients with type 2 diabetes mellitus in China. Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ. ISPOR 17th Annual International Meeting, Washington, DC, Jun 2–6, 2012.

229. PCN42: Health Care Utilization and Costs Among Lung Cancer Patients in China. Zheng Y, Wu J, Xie J, Xie K, Yang H, Liu J, Wu E. ISPOR 17th Annual International Meeting, Washington, DC, Jun 2–6, 2012.
230. Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the United States. Xie J, Diener M, De G, Wu EQ, Namjoshi M. ISPOR 17th Annual International Meeting, Washington, DC, Jun 2–6, 2012.
231. Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis. Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
232. Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis. Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
233. Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
234. Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI). Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
235. Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase. Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
236. Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis. Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
237. Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. 2012 ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2012.
238. Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases. Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M. American Urological Association Annual Meeting, Atlanta, GA, May 19–23, 2012.
239. Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US. Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W. American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY, May 19–22, 2012.

240. Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US. Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W. American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY, May 19–22, 2012.
241. Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation. Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ. Digestive Disease Week, San Diego, CA, May 19–22, 2012.
242. Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment. Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E. American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY, May 19–22, 2012.
243. Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin. Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E. Diabetes UK Professional Conference, Glasgow, UK, Mar 7–9, 2012.
244. Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons. Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH. 165th APA Annual Meeting, Philadelphia, PA, May 5–9, 2012.
245. A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics. Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH. 165th APA Annual Meeting, Philadelphia, PA, May 5–9, 2012.
246. Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke. Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E. 64th American Academy of Neurology Annual Meeting, New Orleans, LA, Apr 21–28, 2012.
247. Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective. Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E. 64th American Academy of Neurology Annual Meeting, New Orleans, LA, Apr 21–28, 2012.
248. The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation. Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ. AMCP's 24th Annual Meeting, San Francisco, CA, Apr 18–20, 2012.
249. Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States. Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D. American Society for Microbiology Conference on Candida and Candidiasis, San Francisco, CA, Mar 29–Apr 2, 2012.
250. Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML). Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ. 8th Annual Meeting of the Hematology/Oncology Pharmacy Association, Orlando, FL, Mar 21–24, 2012.

251. Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin. Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM. Diabetes UK Professional Conference 2012, Glasgow, UK, Mar 7–9, 2012.
252. Assessing preference for deep remission in patients with Crohn’s disease. Sandborn W, Colombel JF, Louis E, Panaccione R, Yang M, Wu E, Mulani P, Chao J. 7th Congress of the European Crohn’s and Colitis Organisation, Barcelona, Spain, Feb 16–18, 2012.
253. Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI). Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S. 2012 Gastrointestinal Cancers Symposium, San Francisco, CA, Jan 19–21, 2012.
254. PMH65: Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder. Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M. International Society for Pharmacoeconomics and Outcomes Research, 2012.
255. Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia. Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ. 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, Dec 10–13, 2011.
256. Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases. Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M. 2011 Breast Cancer Symposium, Chicago, IL, Nov 30–Dec 3, 2011.
257. Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention deficit/ hyperactivity disorder: A retrospective study. Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH. The American Professional Society of ADHD and Related Disorders, Current Concepts and Future Developments Conference, Philadelphia, PA, Nov 19, 2011.
258. Economic burden of psoriasis and diabetes in patients with psoriasis in the United States. Wu EQ, Guerin A, Latremouille-Viau D, Day R, Khan Z, Zhang F. ISPOR 14th Annual European Congress, Madrid, Spain, Nov 5–8, 2011.
259. PIH14 Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009. Shi L, Liu J, Kissinger P, Khan M, Wu E. ISPOR 14th Annual European Congress, Madrid, Spain, Nov 5–8, 2011.
260. PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents. Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E. ISPOR 14th Annual European Congress, Madrid, Spain, Nov 5–8, 2011.
261. Rates and predictors of gonorrhea re-screening among privately insured patients with gonorrhea in 2007-2009. Shi L, Liu J, Kissinger P, Khan M, Wu EQ. ISPOR 14th Annual European Congress, Madrid, Spain, Nov 5–8, 2011.

262. Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM). Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ. ISPOR 14th Annual European Congress, Madrid, Spain, Nov 5–8, 2011.
263. Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes". Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL, Nov 4–9, 2011.
264. Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout. Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL, Nov 4–9, 2011.
265. Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008. Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L. 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, Nov 3–5, 2011.
266. Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis. Latremouille-Viau D, Sawicki GS, Zhang J, Von Wartburg M, Signorovitch J, Wu EQ, Shi L. 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, Nov 3–5, 2011.
267. C-reactive protein levels in moderate to severe crohn's disease patients decreased rapidly and significantly during adalimumab therapy. Ghosh S, Wu E, Bensimon A, Mulani P, Yang M, Chao J. 76th Annual Scientific Meeting of the American College of Gastroenterology, Washington, DC, Oct 28–Nov 2, 2011.
268. Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study. Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH. AACAP/CACAP Joint Annual Meeting, Toronto, ON, Oct 18–23, 2011.
269. Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting. Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E. Annual Meeting of the American College of Clinical Pharmacy Conference, Pittsburgh, PA, Oct 16–19, 2011.
270. Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD. Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E. Annual Meeting of the American College of Clinical Pharmacy, Pittsburgh, PA, Oct 16–19, 2011.
271. Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attentiondeficit/hyperactivity disorder (ADHD). Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ. AMCP's 2011 Educational Conference, Atlanta, GA, Oct 19–21, 2011.
272. Comparative efficacy of guanfacine extended release and atomoxetine for the treatment of oppositional symptoms in children with attentiondeficit/ hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD). Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH. CADDRA 2011 Annual ADHD Conference, Toronto, ON, Oct 14–16, 2011.

273. Complications associated with chemotherapy in patients with metastatic breast cancer. Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S. 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, Sept 23–27, 2011.
274. Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population. Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N. 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield, UK, Sept 22–25, 2010.
275. Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases. Yu AP, Diener M, Wu EQ, Namjoshi M. Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, Sept 16–20, 2011.
276. Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population. Yang H, Marynchenko M, Bron M, Wu E, Yu AP. 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, Sept 12–16, 2011.
277. Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population. Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP. 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, Sep 12–16, 2011.
278. Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation. Zhou S, Wu E, Peng Yu A, Lu M, Sharma H, Graf T. 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, Sept 12–16, 2011.
279. Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes. Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T. 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, Sep 12–16, 2011.
280. Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases. Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M. Breast Cancer Symposium, San Francisco, CA, Sep 8–10, 2011.
281. Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes. Wu EQ, Zhou S, Yu AP, Lu M, Graf T. ADA 71st Scientific Session, San Diego, CA, Jun 24–28, 2011.
282. Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients. Wu EQ, Zhou S, Yu AP, Lu M, Graf T. ADA 71st Scientific Session, San Diego, CA, Jun 24–28, 2011.
283. Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus. Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP. ADA 71st Scientific Session, San Diego, CA, Jun 24–28, 2011.

284. Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence. Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP. ADA 71st Scientific Session, San Diego, CA, Jun 24–28, 2011.
285. Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs. Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ. ADA 71st Scientific Session, San Diego, CA, Jun 24–28, 2011.
286. Utilizing rich data sources to identify patients' subgroups that can benefit most from a treatment. Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, Erder MH. 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD, Jun 6–7, 2011.
287. Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data. Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH. 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD, Jun 6–7, 2011.
288. Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization. Wu E, Zhou S, AP. Y, Lu M, Graf TR. 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA, Jun 4–7, 2011.
289. Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization. Wu E, Zhou S, Yu AP, Lu M, Graf TR. 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA, Jun 4–7, 2011.
290. Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting. Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA. ASCO Annual Meeting, Chicago, IL, Jun 3–7, 2011.
291. Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases. Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW. ASCO Annual Meeting, Chicago, IL, Jun 3–7, 2011.
292. Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML). Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A. ASCO Annual Meeting, Chicago, IL, Jun 3–7, 2011.
293. Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting. Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M. ASCO Annual Meeting, Chicago, IL, Jun 3–7, 2011.
294. The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents. Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V. ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011.
295. Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011.

296. Improved indirect treatment comparisons for comparative effectiveness research. Signorovitch J, Navarro R, Betts K, Wu EQ. ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011.
297. PRS7 Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis. Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lizheng S. ISPOR 16th Annual International Meeting, Baltimore, MD, May 21–25, 2011.
298. Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting. Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ. Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, May 12–14, 2011.
299. Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients. Yang H, Yu A, Yim Y, Yu E, Wu E. AMCP's 23rd Annual Meeting, Minneapolis, MN, Apr 27–29, 2011.
300. Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy. Guerin A, Lin J, Jhaveri M, Wu E, Alpert J. AMCP's 23rd Annual Meeting, Minneapolis, MN, Apr 27–29, 2011.
301. Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy. Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ. 60th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, New Orleans, LA, Apr 2–5, 2011.
302. Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis. Papp K, Wu E, Goldblum O, Gupta S. 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 4–8, 2011.
303. Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen. Yang H, Yu AP, Yim Y, Yu E, Wu E. 2011 Gastrointestinal Cancers Symposium, San Francisco, CA, Jan 20–22, 2011.
304. Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia. Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ. 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 4–7, 2010.
305. The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML). Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A. 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 4–7, 2010.
306. Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma. Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N. 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 4–7, 2010.
307. Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers. Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI. CHEST 2010 Annual Meeting, Vancouver, BC, Oct 30–Nov 4, 2010.

308. Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers. Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI. CHEST 2010 Annual Meeting, Vancouver, BC, Oct 30–Nov 4, 2010.
309. Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers. Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI. CHEST 2010 Annual Meeting Vancouver, BC, Oct 30–Nov 4, 2010.
310. Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis. Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J. 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD, Oct 21–23, 2010.
311. Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis. Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L. 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD, Oct 21–23, 2010.
312. Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis. Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ. High Blood Pressure Research 2010 Scientific Sessions, HBPR Washington, DC, Oct 13–16, 2010.
313. Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX). Yim Y, Wu EQ, Yu AP, Yang HY, Yu E. 35th ESMO Congress, Milan, Italy, Oct 8–12, 2010.
314. ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life. Menter A, Signorovitch J, Parikh K, Yu A, Wu E, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani P. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
315. Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy. Duffin K, Guérin A, Yang H, Wu E, Yu A, Gupta S, Goldblum O, Bao Y, Mulani P. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
316. Adalimumab provides health-related quality-of life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy. Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
317. Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy. Papp K, Guérin A, Parikh K, Signorovitch J, Yu AP, Wu EQ, Okun M, Gupta SR, Bao Y, Mulani PM. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
318. Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity. Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.

319. Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment. Papp K, Signorovitch J, Yang H, Yu AP, Wu EQ, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
320. Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting. Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM. Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, Oct 6–10, 2010.
321. Selecting the optimal target population for formulary coverage. Wu EQ, Yu D, Xie J, Gu. ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, Sep 5–7, 2010.
322. PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort. Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E. ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, Sep 5–7, 2010.
323. T1065: Impact of Nighttime Symptoms (NTS) on Treatment Patterns and Healthcare Costs Among Gastroesophageal Reflux Disease (GERD) Patients. Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD. Digestive Disease Week, New Orleans, LA, Jun 1–6, 2010.
324. Aliskiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis. Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
325. Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region. Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
326. Comparative Effectiveness Research for Personalized Medicine. Signorovitch J, Wu EQ, We LJ. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
327. Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis. Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
328. Economic burden of exacerbations in chronic obstructive pulmonary disease. Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
329. Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBS) in patients with hypertension. Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
330. Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short- and long-term negative impacts on health care resource utilization and costs. Guerin A, Bollu V,

- Guo A, Wu E, Yu A, Sirulnik L, Griffin J. ISPOR 15th Annual International Meeting, Atlanta, GA., May 15–19, 2010.
331. PCN47 Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML). Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J. ISPOR 15th Annual International Meeting, Atlanta, GA, May 15–19, 2010.
332. M1047 Quality-of-Life Benefits for Adalimumab-Treated Patients with Moderate to Severe Crohn’s Disease are Predicted by Early Mucosal Healing Status. Rutgeerts PJ, Thakkar R, Wu EQ, Kaltenboeck A, Yang M, Mulani P, Chao J. Digestive Disease Week, New Orleans, LA, May 1–5, 2010.
333. Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs. Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ. AMCP’s 22nd Annual Meeting, San Diego, CA, Apr 7–10, 2010.
334. Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder. Wu EQ, Signorovitch JE, Bao Y, Mulani PM. American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL, Mar 5–9, 2010.
335. Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder. Wu E, Signorovitch J, Mulani P, Bao Y. 68th Annual Meeting of the American Academy of Dermatology, Miami, FL, Mar 5–9, 2010.
336. Direct and indirect economic burden of employees with moderate to severe psoriasis. Reich K, Wu E, Mulani P, Gupta S. 68th Annual Meeting of the American Academy of Dermatology, Miami, FL, Mar 5–9, 2010.
337. Economic burden of comorbidities in patients with psoriasis. Kimball A, Wu E, Mulani P, Bao Y. 68th Annual Meeting of the American Academy of Dermatology, Miami, FL, Mar 5–9, 2010.
338. Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept. Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y. American Academy of Dermatology 69th Annual Meeting, New Orleans, LA, Feb 4–8, 2010.
339. Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis. Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y. American Academy of Dermatology 69th Annual Meeting, New Orleans, LA, Feb 4–8, 2010.
340. Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia. Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec 5–8, 2009.
341. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. Wu EQ, Bollu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec 5–8, 2009.

342. The costs of treatment failure gout: A claims-based analysis. Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A. American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, Nov 6–11, 2010.
343. Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram. Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H. AMCP's 2009 Educational Conference, San Antonio, TX, Oct 7–9, 2009.
344. Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension. Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K. AMCP's 2009 Educational Conference, San Antonio, TX, Oct 7–9, 2009.
345. The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression. Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H. AMCP's 2009 Educational Conference, San Antonio, TX, Oct 7–9, 2009.
346. Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c<7.0. Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S. 45th EASD Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria, Sep 30–Oct 2, 2009.
347. S1030: Increased Risk of Psychiatric Disorders in Young Patients with Crohn's Disease. Loftus EV, Guérin A, Yu AP, Wu E, Chao J, Mulani P. Digestive Disease Week Annual Conference, Chicago, IL, May 30–Jun 4, 2009.
348. S1136: Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease. Rubin DT, Bensimon AG, Yu AP, Wu E, Chao J, Mulani P. Digestive Disease Week Annual Conference, Chicago, IL, May 30–Jun 4, 2009.
349. Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia. Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsaneva M, Yu P, Wu EQ, Signorovitch J, Demetri GD. ASCO Annual Meeting, Orlando, FL, May 29–Jun 2, 2009.
350. Real world treatment patterns of gastrointestinal stromal tumor patients. Wu EQ. ASCO Annual Meeting, Orlando, FL, May 29–Jun 2, 2009.
351. Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib. Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD. ASCO Annual Meeting, Orlando, FL, May 29–June 2, 2009.
352. Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data. Wu EQ, Signorovitch J, Yu A. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
353. Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs. Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
354. Economic assessment of second-line treatment: Switching from a generic SSRI to escitalopram, an SNRI, or another generic SSRI by patients with major depressive disorder (MDD).

- Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Erder MH, Bose A. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
355. The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI. Lauzon V, Kaltenboeck A, Yu AP, Ramakrishnan K, Marynchenko M, Wu EQ, Ben-Hamadi R, Erder MH, Bose A. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
356. Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR. Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
357. Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia. Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
358. Number-needed-to-treat (NNT) analysis: Remission rates for adalimumab vs. Infliximab in Crohn's disease. Jonasson S, Kaltenboeck A, Horn C, Wu E, Majethia S, Mulani P, Chao J. ISPOR 14th Annual International Meeting, Orlando, FL, May 16–20, 2009.
359. Adalimumab's benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories. Kimball AB, Wu EQ, Mulani P, Gupta S. 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA, Mar 6–10, 2009.
360. Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life. Menter A, Wu EQ, Mulani P. 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA, Mar 6–10, 2009.
361. Rate of dosage escalation in patients with Crohn's disease treated with infliximab. Plevy S, Wu E, Yu A, Chao J, Mulani P. Canadian Digestive Diseases Week 2009, Banff, AB, Feb 27–Mar 2, 2009.
362. P246: Young patients with Crohn's disease are at increased risk for psychiatric disorders. Loftus E, Guérin A, Yu A, Wu E, Chao J, Mulani P. European Crohn's & Colitis Organisation 4th Congress, Hamburg, Germany, Feb 5–7, 2009.
363. Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist-Naïve Patients with Crohn's Disease. Loftus E, Feagan B, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P. American College of Gastroenterology 2008 Annual Meeting, Orlando, FL, Oct 3–8, 2008.
364. Health-Related Quality Of Life in TNF-Antagonist-Naïve Patients with Crohn's Disease during Short- and Long-Term Adalimumab Treatment. Rubin D, Rutgeerts P, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P. American College of Gastroenterology 2008 Annual Meeting, Orlando, FL, Oct 3–8, 2008.
365. Infliximab Dosage-Increase Rate in Patients with Crohn's Disease. Plevy S, Wu EQ, Yu A, Chao J, Mulani P. American College of Gastroenterology 2008 Annual Meeting, Orlando, FL, Oct 3–8, 2008.
366. Achieving Glycemic Goal with Initial Combination Therapy versus Sequential Augmentation Therapy using Metformin and Pioglitazone. Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW. 44th EASD Meeting, Rome, Italy, Sep 7–11, 2008.

367. Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs. Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M. 21st ECNP Congress, Barcelona, Spain, Aug 30–Sep 3, 2008.
368. Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram. Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N. 21st ECNP Congress, Barcelona, Spain, Aug 30–Sep 03, 2008.
369. Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies. Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW. American Diabetes Association's 68th Scientific Sessions, San Francisco, CA, Jun 6–10, 2008.
370. M1033: Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs). Chey WD, Mody R, Chen L, Kothari S, Persson B, Wu E, Lu M. Digestive Disease Week, San Francisco, CA, May 17–22, 2008.
371. M1041: Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? A Community-Based US Survey Study. Chey WD, Mody R, Kothari S, Wu E, Chen L, Persson B, Beaulieu N, Lu M. Digestive Disease Week, San Diego, CA, May 17–22, 2008.
372. T1061: Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohn's disease patients who failed infliximab (CHOICE trial). Lichtiger S, Present DH, Wu E, Beaulieu N, Kent JD, Lomax KG, Chao J, Mulani P. Digestive Disease Week, San Diego, CA, May 17–22, 2008.
373. T1062: Improvement in Work Productivity with Adalimumab in Crohn's Disease Patients Who Failed Prior Infliximab: An Analysis of the CHOICE Trial. Lichtiger S, Present DH, Persson B, Wu E, Kent JD, Lomax KG, Chao J, Mulani P. Digestive Disease Week, San Diego, CA, May 17–22, 2008.
374. T1197: A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn's Disease. Loftus EV, Colombel J-F, Johnson SJ, Wu E, Chao J, Mulani P. Digestive Disease Week, San Diego, CA, May 17–22, 2008.
375. Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease. Kane S, Wu EQ, Chen L, Yu A, Tsaneva M, Chao J, Mulani P. ISPOR 13th Annual International Meeting, Toronto, ON, May 3–7, 2008.
376. Clinical and Economic Outcomes among Women Using Levonorgestrel-Releasing Intrauterine System (LNG-IUS). Yu A, Wu EQ, Persson B, Chang J, Costales C, Gricar J. ISPOR 13th Annual International Meeting, Toronto, ON, May 3–7, 2008.

377. Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI. Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A. ISPOR 13th Annual International Meeting, Toronto, ON, May 3–7, 2008.
378. WH3: Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS). Yu A, Wu E, Perrson B, Chang J, Costales A, Gricar J. ISPOR 13th Annual International Meeting, Toronto, ON, May 3–7, 2008.
379. PGI17: Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with crohn's disease. Kane S, Wu E, Chen L, Yu A, Tsaneva M, Chao J, Mulani P. ISPOR 13th Annual International Meeting, Toronto, ON, May 3–7, 2008.
380. Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study. Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H. American College of Gastroenterology, Philadelphia, PA, Oct 12–17, 2007.
381. Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens. Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Lu M. American College of Gastroenterology, Philadelphia, PA, Oct 12–17, 2007.
382. Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes. Loftus EV, Wu EQ, Yu AP. American College of Gastroenterology, Philadelphia, PA, Oct 12–17, 2007.
383. Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn's Disease in the CHARM Trial. Colombel JF, Wu EQ, Yu AP. American College of Gastroenterology, Philadelphia, PA, Oct 12–17, 2007.
384. Antidepressant Treatment Patterns and Related Costs among U.S. Employees. Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobelle C, Ben-Hamadi R. Institute on Psychiatric Services (APA-I), New Orleans, LA, Oct 11–14, 2007.
385. Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram. Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M. Institute on Psychiatric Services (APA-I), New Orleans, LA, Oct 11–14, 2007.
386. Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay. Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ. American Society of Nuclear Cardiology, San Diego, CA, Sep 6–9, 2007.
387. Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram. Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M. International Health Economics Association, Copenhagen, Denmark, Jul 8–11, 2007.
388. Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIS. Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, Jun 13–16, 2007.

389. Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients. Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J. ASCO Annual Meeting, Chicago, IL, Jun 1–5, 2007.
390. Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI). Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buessing M. ISPOR 12th Annual International Meeting, Arlington, VA, May 19–23, 2007.
391. Lower Disease Activity And Clinical Remission Are Associated with Reduced Hospitalization Risk In Crohn’s Disease. Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. ISPOR 12th Annual International Meeting, Arlington, VA, May 19–23, 2007.
392. MH2: Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants. Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M. 2007 International Society for Pharmacoeconomics and Outcomes Research, May 19–23, 2007.
393. Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?. Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. American Geriatrics Society Annual Scientific Meeting, Seattle, WA, May 2–6, 2007.
394. Treatment Cost of Gout in an Elderly Population: A Claims Database Analysis. Wu EQ, Patel P, Krishnan E, Yu AP. American Geriatrics Society Annual Scientific Meeting, Seattle, WA, May 26, 2007.
395. Healthcare Cost of Gout in an Elderly Population: A Claims Database Analysis. Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. American Geriatrics Society Annual Scientific Meeting, Seattle, WA, May 2–6, 2007.
396. Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram. Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M. European College of Neuropsychopharmacology (ECNP) Regional Meeting, Sofia, Bulgaria, Apr 27–29, 2007.
397. Assessing Step Therapy/Generic Switching: Clinical and Economic implications of Acquisition Costs vs. Total Health Care Costs Paradigm. Wu EQ, Greenberg P, Erder MH. Congressional Budget Office, Washington, DC, 2007.
398. Health Economics Impact in the Treatment of Depression. Navarro R, Wu EQ. National Association of Managed Care Physicians (NAMCP), 2007.
399. PGI13: Lower disease activity and clinical remission are associated with reduced hospitalization risk in Crohn’s disease. Wu E, Yu A, Atanasov P, Tang J, Pollack P, Lomax K, Mulani P. International Society for Pharmacoeconomics and Outcomes Research, 2007.
400. HI1: Adult Economic Status and Obesity in the United States: 2000–2002. Wu E, Xie J, Crémieux P, Sullivan P. International Society for Pharmacoeconomics and Outcomes Research, 2006.
401. MH4: Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies. Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A. International Society for Pharmacoeconomics and Outcomes Research, 2006.

402. PCN33: Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D health utility in metastatic hormone-refractory prostate cancer patients. Wu E, Mulani P, Farrell M, Sleep D. International Society for Pharmacoeconomics and Outcomes Research, 2006.
403. POB7: Obesity and quality of life in the United States: 2000–2002. Wu E, Xie J, Sullivan P. International Society for Pharmacoeconomics and Outcomes Research, 2006.
404. Annual Costs Associated with Diagnosis of Uterine Fibroids. Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Spalding J, Stang P. The American College of Obstetricians and Gynecologists, 2006.
405. Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies. Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A. American Psychiatric Association, 2006.
406. Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients. Yu AP, Wu EQ, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M. American Diabetes Association, 2006.
407. Health-Related Quality of Life of Anemia Patients in the U.S. Cremieux P, Xie J, Wu EQ, Castor A. International Society for Pharmacoeconomics and Outcomes Research Asia-Pacific, 2006.
408. Health-Related Quality of Life of Stroke Survivors in the U.S. Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia-Pacific, 2006.
409. Inpatient and Emergency Department Utilization of Persistent Asthma Patients. Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST. American Thoracic Society, 2006.
410. Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective. Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE. The American College of Obstetricians and Gynecologists, 2006.
411. Loss of Treatment Response among Crohn's Disease Patients Receiving Infliximab Maintenance Therapy. Wu EQ, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P. AMCP's 18th Annual Meeting, Seattle, WA, Apr 5–8, 2006.
412. Obesity's Impact on Diabetes Patients' Health-Related Quality of Life in the U.S. Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia-Pacific, 2006.
413. Patterns of Antidepressant Treatment Response in an Employed Population. Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E. American Psychiatric Association, 2006.
414. PMH7: Annual costs associated with patterns of antidepressant treatment response among employees. Wu E, Birnbaum H, Ben-Hamadi R, Yu A, Tang J, Greenberg P, Gilloteau I, Smadja E. International Society for Pharmacoeconomics and Outcomes Research, 2006.
415. Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes. Wu EQ, Yu AP, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M, Yang E. American Diabetes Association.

416. PMH37: The economic burden of schizophrenia in the United States in 2002. Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Moulis M, Aggarwal J. International Society for Pharmacoeconomics and Outcomes Research, 2005.
417. PMH49: Estimating annual US prevalence of schizophrenia in 2002. Wu E, Birnbaum H, Aggarwal J, Moulis M. International Society for Pharmacoeconomics and Outcomes Research, 2005.
418. POS1: Using a budget impact model to predict first-year use of a new osteoporosis therapy. Sasser A, Rousculp M, Birnbaum H, Moyneur E, Wu E, Marcus R. International Society for Pharmacoeconomics and Outcomes Research, 2005.
419. PRS3: Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones. Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G. International Society for Pharmacoeconomics and Outcomes Research, 2005.
420. Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP. Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J. International Society for Pharmacoeconomics and Outcomes Research.
421. Development of a COPD Severity Score in ClaimsDatabase. Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y. International Society for Pharmacoeconomics and Outcomes Research European.
422. Direct Health Care Costs of Schizophrenia in the United States: 2002. Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L. International Society for Pharmacoeconomics and Outcomes Research.
423. Economic Burden of Lost Productivity due to Schizophrenia in the United States: 2002. Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D. American Psychiatric Association.
424. Employment and Income Associated with Obesity and Overweight in the US. Wu EQ, Xie J, Sullivan PW. North American Association for the Study of Obesity.
425. Employment and Income Associated with Obesity and Overweight in the US. Colice G, Crivera C, Vearghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB. AMCP 2005.
426. Healthcare Costs of Patients with Persistent Asthma. Colice G, Crivera C, Varghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB. AMCP's 2005 Educational Conference, Nashville, TN, Oct 5–8, 2005.
427. Quality of Life of Obese Adults in the US. Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW. International Society for Quality of Life Research.
428. Systematic Differences in Subjective vs. Societal Preferences. Sullivan PW, Ghushchyan V, Wu EQ. International Society for Quality of Life Research.
429. Using Claims Data to Estimate the Annual Prevalence of Schizophrenia in the United States, 2002. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. International Society for Pharmacoeconomics and Outcomes Research European, 2005.
430. Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy. Rousculp MD, Sasser AC, Birnbaum HG, Moyneur E, Wu EQ, Mallet D, Marcus R. AMCP 2005.

431. Comorbidities and Cost Associated with Bipolar Disorder. Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC. American Public Health Association, 2004.
432. Cost and Comorbidities Associated with Atrial Fibrillation. Wu EQ, Howard BG, Mareva MN. NASPE - Heart Rhythm Society.
433. Cost and Comorbidities Associated with Bipolar Disorder. Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC. International Society for Pharmacoeconomics and Outcomes Research.
434. Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Perspective. Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R. International Society for Pharmacoeconomics and Outcomes Research.
435. Drug Treatment Patterns of Bipolar Disorder and Associated Costs. Wu EQ, Birnbaum H, Greenberg P, Huang Z, Kessler R, Parece A, T. V. National Institute of Mental Health's New Clinical Drug Evaluation Unit Meeting, 2004.
436. PCV22: Cost and comorbidities associated with atrial fibrillation in different age groups. Wu E, Birnbaum H, Milena M. International Society for Pharmacoeconomics and Outcomes Research, 2004.
437. PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis. Rosberg J, Oster E, Wu E, Fastenau J, Piech C. International Society for Pharmacoeconomics and Outcomes Research 2003.
438. PNP16: The comparison of different methods for determining the impact of migraine prophylaxis on costs. Barlev A, Globe D, Wu E, Yu W, Johnson K. 2003 International Society for Pharmacoeconomics and Outcomes Research, 2003.
439. PRP13: Assessing the cost implications of combined pharmacotherapy in the long term management of asthma. Wu E, Johnson K, Nichol M. International Society for Pharmacoeconomics and Outcomes Research, 2003.
440. Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma. Wu EQ, Johnson KA, Nichol MB. International Society for Pharmacoeconomics and Outcomes Research.
441. PDB6: Factors associated with high-risk diabetic patients in the California Medicaid populations (Medi-Cal). Chaikledkaew U, Wu E, Johnson K. International Society for Pharmacoeconomics and Outcomes Research, 2003.
442. PDB10: A Methodology to identify high-risk patients with diabetes in the California Medicaid population (Medi-Cal). Chaikledkaew U, Wu E, Johnson K. International Society for Pharmacoeconomics and Outcomes Research, 2003.
443. PMD3: Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ATE). Wu E, Johnson K, Nichol M. International Society for Pharmacoeconomics and Outcomes Research, 2003.
444. PMD4: Performance of two conditional expectation methods under unobserved selection bias. Wu E, Nichol M, Johnson K. International Society for Pharmacoeconomics and Outcomes Research, 2003.

445. Alternative Management Strategies for Dyspepsia. Wu E, Hay J. International Society for Pharmacoeconomics and Outcomes Research, 2001.
446. Survival and Nursing Home Free Survival (NHFS) of Alzheimer's Disease (AD) Patients. Wu EQ, Hay J. International Society for Pharmacoeconomics and Outcomes Research, 2001.
447. Comparative Econometric Models of Medical Costs. Wu EQ, Hay JW. International Society for Pharmacoeconomics and Outcomes Research, 2000.
448. The Impact of an Over-the-Counter Migraine Medication on Quality of Life. Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J. International Society for Pharmacoeconomics and Outcomes Research.